<article title='Aspirin'><paragraph><template><target>Use dmy dates</target><arg name="date">January 2013</arg></template><template><target>Good article</target></template><template><target>Infobox drug</target><arg name="Watchedfields"><space/>changed
</arg><arg name="verifiedrevid"><space/>464364671
</arg><arg name="IUPAC_name"><space/>2-(acetoxy)benzoic acid 
</arg><arg name="image"><space/>Aspirin-skeletal.svg
</arg><arg name="image2"><space/>Aspirin-B-3D-balls.png

<space/></arg><arg name="pronounce"><space/>acetylsalicylic acid {{IPAc-en|ə|ˌ|s|iː|t|əl|ˌ|s|æ|l|ɨ|ˈ|s|ɪ|l|ɨ|k}}
</arg><arg name="Drugs.com"><space/>{{drugs.com|monograph|aspirin}}
</arg><arg name="MedlinePlus"><space/>a682878
</arg><arg name="pregnancy_AU"><space/>C
</arg><arg name="pregnancy_US"><space/>C
</arg><arg name="pregnancy_US_comment"><space/>D in the 3rd trimester
</arg><arg name="legal_AU"><space/>S2
</arg><arg name="legal_AU_comment"><space/>except when given intravenously (in which case it is schedule 4), used in animal medicine (schedule 5/6) or when the dose is higher than usual.
</arg><arg name="legal_UK"><space/>GSL
</arg><arg name="legal_US"><space/>OTC
</arg><arg name="routes_of_administration"><space/>Most commonly oral, also rectal, [[lysine acetylsalicylate]] may be given [[intravenous therapy|intravenously]] or [[intramuscular injection|intramuscularly]]

<space/></arg><arg name="bioavailability"><space/>80–100%<ref name<space/></arg><arg name="protein_bound"><space/>80–90%<ref name<space/></arg><arg name="metabolism"><space/>[[Liver|Hepatic]], ([[CYP2C19]] and possibly [[CYP3A]]), some is also hydrolysed to salicylate in the gut wall.<ref name<space/></arg><arg name="elimination_half-life"><space/>Dose-dependent; 2–3 hours for low doses, 15–30 hours for large doses.<ref name<space/></arg><arg name="excretion"><space/>Urine (80–100%), sweat, saliva, feces<ref name<space/></arg><arg name="IUPHAR_ligand"><space/>4139
</arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number"><space/>50-78-2
</arg><arg name="ATC_prefix"><space/>A01
</arg><arg name="ATC_suffix"><space/>AD05
</arg><arg name="ATC_supplemental"><space/>{{ATC|B01|AC06}}, {{ATC|N02|BA01}}
</arg><arg name="PubChem"><space/>2244
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB00945
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>2157
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>R16CO5Y76E
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG"><space/>D00109
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>15365
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>25
</arg><arg name="PDB_ligand"><space/>AIN
<space/></arg><arg name="C">9<space/></arg><arg name="H">8<space/></arg><arg name="O">4
</arg><arg name="molecular_weight"><space/>180.157 g/mol
</arg><arg name="smiles"><space/>O</arg><arg name="InChI"><space/>1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>BSYNRYMUTXBXSQ-UHFFFAOYSA-N
</arg><arg name="synonyms"><space/>2-acetoxybenzoic acid<br />acetylsalicylate<br />acetylsalicylic acid<br />O-acetylsalicylic acid
</arg><arg name="density"><space/>1.40
</arg><arg name="melting_point"><space/>135
</arg><arg name="boiling_point"><space/>140
</arg><arg name="boiling_notes"><space/>(decomposes)
</arg><arg name="solubility"><space/>3
</arg></template></paragraph><preblock><preline><bold>Aspirin</bold>, also known as<space/><bold>acetylsalicylic acid</bold><space/>(<bold>ASA</bold>), is a<space/><link><target>salicylate</target></link><space/><link><target>medication</target></link>, often used to treat<space/><link><target>analgesic</target><part>pain</part></link>, fever, and<space/><link><target>inflammation</target></link>.<extension extension_name='ref' name="MD"></extension><space/>Aspirin also has an<space/><link><target>Antiplatelet drug</target><part>antiplatelet</part></link><space/>effect by stopping the binding together of<space/><link><target>platelet</target><trail>s</trail></link><space/>and preventing a patch over damaged walls of blood vessels. Aspirin is also used long-term, at low doses, to help prevent<space/><link><target>myocardial infarction</target><part>heart attacks</part></link>,<space/><link><target>stroke</target><trail>s</trail></link>, and<space/><link><target>thrombus</target><part>blood clot</part></link><space/>formation in people at high risk of developing blood clots.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Lewis<space/></arg><arg name="first1"><space/>H. D.<space/></arg><arg name="last2"><space/>Davis<space/></arg><arg name="first2"><space/>J. W.<space/></arg><arg name="last3"><space/>Archibald<space/></arg><arg name="first3"><space/>D. G.<space/></arg><arg name="last4"><space/>Steinke<space/></arg><arg name="first4"><space/>W. E.<space/></arg><arg name="last5"><space/>Smitherman<space/></arg><arg name="first5"><space/>T. C.<space/></arg><arg name="last6"><space/>Doherty Je<space/></arg><arg name="first6"><space/>J. E.<space/></arg><arg name="last7"><space/>Schnaper<space/></arg><arg name="first7"><space/>H. W.<space/></arg><arg name="last8"><space/>Lewinter<space/></arg><arg name="first8"><space/>M. M.<space/></arg><arg name="last9"><space/>Linares<space/></arg><arg name="first9"><space/>E.<space/></arg><arg name="last10"><space/>Pouget<space/></arg><arg name="first10"><space/>J. M.<space/></arg><arg name="last11"><space/>Sabharwal<space/></arg><arg name="first11"><space/>S. C.<space/></arg><arg name="last12"><space/>Chesler<space/></arg><arg name="first12"><space/>E.<space/></arg><arg name="last13"><space/>Demots<space/></arg><arg name="first13"><space/>H.<space/></arg><arg name="title"><space/>Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina<space/></arg><arg name="journal"><space/>New England Journal of Medicine<space/></arg><arg name="volume"><space/>309<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>396–403<space/></arg><arg name="year"><space/>1983<space/></arg><arg name="pmid"><space/>6135989<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1056/NEJM198308183090703<space/></arg></template></extension><space/>Low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.<extension extension_name='ref' name="anticoag"><template><target>Cite journal</target><arg name="last1">Julian<space/></arg><arg name="first1">D G<space/></arg><arg name="author2">D A Chamberlain<space/></arg><arg name="author3">S J Pocock<space/></arg><arg name="title">A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial<space/></arg><arg name="journal">BMJ<space/></arg><arg name="volume">313<space/></arg><arg name="issue"><space/>7070<space/></arg><arg name="pages">1429–1431<space/></arg><arg name="publisher">British Medical Journal<space/></arg><arg name="date"><space/>24 September 1996<space/></arg><arg name="pmid">8973228<space/></arg><arg name="pmc">2353012<space/></arg><arg name="doi">10.1136/bmj.313.7070.1429</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Krumholz<space/></arg><arg name="first1"><space/>H. M.<space/></arg><arg name="last2"><space/>Radford<space/></arg><arg name="first2"><space/>M. J.<space/></arg><arg name="last3"><space/>Ellerbeck<space/></arg><arg name="first3"><space/>E. F.<space/></arg><arg name="last4"><space/>Hennen<space/></arg><arg name="first4"><space/>J.<space/></arg><arg name="last5"><space/>Meehan<space/></arg><arg name="first5"><space/>T. P.<space/></arg><arg name="last6"><space/>Petrillo<space/></arg><arg name="first6"><space/>M.<space/></arg><arg name="last7"><space/>Wang<space/></arg><arg name="first7"><space/>Y.<space/></arg><arg name="last8"><space/>Kresowik<space/></arg><arg name="first8"><space/>T. F.<space/></arg><arg name="last9"><space/>Jencks<space/></arg><arg name="first9"><space/>S. F.<space/></arg><arg name="title"><space/>Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes<space/></arg><arg name="journal"><space/>Circulation<space/></arg><arg name="volume"><space/>92<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>2841–2847<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="pmid"><space/>7586250<space/></arg><arg name="doi"><space/>10.1161/01.CIR.92.10.2841</arg></template></extension><space/>Aspirin may be effective at preventing certain types of cancer, particularly<space/><link><target>colorectal cancer</target></link>.<extension extension_name='ref' name="thelancet.com"><template><target>cite journal</target><arg name="doi">10.1016/S1470-2045(12)70112-2</arg><arg name="title">Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials</arg><arg name="year">2012</arg><arg name="last1">Algra</arg><arg name="first1">Annemijn M</arg><arg name="last2">Rothwell</arg><arg name="first2">Peter M</arg><arg name="journal">The Lancet Oncology</arg><arg name="volume">13</arg><arg name="issue">5</arg><arg name="pages">518–27</arg><arg name="pmid">22440112</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1016/S0140-6736(11)61720-0</arg><arg name="title">Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials</arg><arg name="year">2012</arg><arg name="last1">Rothwell</arg><arg name="first1">Peter M</arg><arg name="last2">Price</arg><arg name="first2">Jacqueline F</arg><arg name="last3">Fowkes</arg><arg name="first3">F Gerald R</arg><arg name="last4">Zanchetti</arg><arg name="first4">Alberto</arg><arg name="last5">Roncaglioni</arg><arg name="first5">Maria Carla</arg><arg name="last6">Tognoni</arg><arg name="first6">Gianni</arg><arg name="last7">Lee</arg><arg name="first7">Robert</arg><arg name="last8">Belch</arg><arg name="first8">Jill FF</arg><arg name="last9">Wilson</arg><arg name="first9">Michelle<space/></arg><arg name="journal">The Lancet</arg><arg name="volume">379</arg><arg name="issue">9826</arg><arg name="pages">1602–1612</arg><arg name="last10">Mehta</arg><arg name="first10">Ziyah</arg><arg name="last11">Meade</arg><arg name="first11">Tom W</arg><arg name="displayauthors">9<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1016/S0140-6736(12)60209-8</arg><arg name="title">Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials</arg><arg name="year">2012</arg><arg name="last1">Rothwell</arg><arg name="first1">Peter M</arg><arg name="last2">Wilson</arg><arg name="first2">Michelle</arg><arg name="last3">Price</arg><arg name="first3">Jacqueline F</arg><arg name="last4">Belch</arg><arg name="first4">Jill FF</arg><arg name="last5">Meade</arg><arg name="first5">Tom W</arg><arg name="last6">Mehta</arg><arg name="first6">Ziyah</arg><arg name="journal">The Lancet</arg><arg name="volume">379</arg><arg name="issue">9826</arg><arg name="pages">1591–1601</arg><arg name="pmid">22440947</arg></template></extension></preline></preblock><preblock><preline>The main<space/><link><target>adverse drug reaction</target><part>side effects</part></link><space/>of aspirin are<space/><link><target>gastrointestinal</target></link><space/><link><target>gastric ulcer</target><part>ulcers</part></link>, stomach bleeding, and<space/><link><target>tinnitus</target><part>ringing in the ears</part></link>, especially with higher doses. While daily aspirin can help prevent a clot-related stroke, it may increase risk of a bleeding stroke (hemorrhagic stroke).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Daily aspirin therapy: Understand the benefits and risks</arg><arg name="url">http://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/daily-aspirin-therapy/art-20046797</arg><arg name="website">MayoClinic.org</arg><arg name="publisher">Mayo Clinic</arg><arg name="accessdate">21 March 2015</arg></template></extension><space/>In children and adolescents, aspirin is not recommended for<space/><link><target>flu-like symptoms</target></link><space/>or viral illnesses, because of the risk of<space/><link><target>Reye's syndrome</target></link>.<extension extension_name='ref' name="BMJ2002-Macdonald"><template><target>Cite journal</target><arg name="author">Macdonald S</arg><arg name="title">Aspirin use to be banned in under 16-year olds</arg><arg name="journal">BMJ</arg><arg name="volume">325</arg><arg name="issue">7371</arg><arg name="pages">988c–988</arg><arg name="year">2002</arg><arg name="pmid"><space/>12411346<space/></arg><arg name="pmc">1169585</arg><arg name="doi">10.1136/bmj.325.7371.988/c</arg></template></extension></preline></preblock><preblock><preline>Aspirin is part of a group of medications called<space/><link><target>nonsteroidal anti-inflammatory drug</target><trail>s</trail></link><space/>(NSAIDs), but differs from most other NSAIDs in the<space/><link><target>nonsteroidal anti-inflammatory drugs#Mechanism of action</target><part>mechanism of action</part></link>. The salicylates have similar effects (antipyretic, anti-inflammatory, analgesic) to the other NSAIDs and inhibit the same enzyme<space/><link><target>cyclooxygenase</target></link><space/>(COX), but aspirin does so in an<space/><link><target>irreversible inhibition</target><part>irreversible</part></link><space/>manner and, unlike others, affects the COX-1 variant more than the COX-2 variant of the enzyme.<extension extension_name='ref' name="Goodman and Gilman's"><template><target>Cite book</target><arg name="last">Burke<space/></arg><arg name="first">Anne<space/></arg><arg name="last2">Smyth<space/></arg><arg name="first2">Emer<space/></arg><arg name="last3">FitzGerald<space/></arg><arg name="first3">Garret A.<space/></arg><arg name="chapter">26: Analgesic Antipyretic and Antiinflammatory Agents<space/></arg><arg name="title">[[Goodman & Gilman's The Pharmacological Basis of Therapeutics]]<space/></arg><arg name="editor1-first">Laurence L.<space/></arg><arg name="editor1-last">Brunton<space/></arg><arg name="editor2-first">John S.<space/></arg><arg name="editor2-last">Lazo<space/></arg><arg name="editor3-first">Keith<space/></arg><arg name="editor3-last">Parker<space/></arg><arg name="publisher">McGraw-Hill<space/></arg><arg name="year">2006<space/></arg><arg name="edition">11<space/></arg><arg name="isbn">978-0-07-142280-2<space/></arg><arg name="location">New York<space/></arg><arg name="pages">671–716</arg></template></extension></preline></preblock><preblock><preline>The therapeutic properties of<space/><link><target>willow tree</target></link><space/>bark have been known for at least 2,400 years, with<space/><link><target>Hippocrates</target></link><space/>prescribing it for headaches.<extension extension_name='ref'>http://www.bloomberg.com/news/articles/2012-03-20/hippocrates-s-3-cent-aspirin-once-a-day-may-keep-cancer-away</extension><space/><link><target>Salicylic acid</target></link>, the<space/><link><target>active ingredient</target></link><space/>of aspirin, was first isolated from the bark of the willow tree in 1763 by<space/><link><target>Edward Stone (clergyman)</target><part>Edward Stone</part></link><space/>of<space/><link><target>Wadham College</target></link>,<space/><link><target>University of Oxford</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Stone Edmund<space/></arg><arg name="title">An Account of the Success of the Bark of the Willow in the Cure of Agues. In a Letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edmund Stone, of Chipping-Norton in Oxfordshire<space/></arg><arg name="journal">Philosophical Transactions of the Royal Society of London<space/></arg><arg name="volume">53<space/></arg><arg name="pages">195–200<space/></arg><arg name="year">1763<space/></arg><arg name="url">https://books.google.com/books?id</arg><arg name="jstor">105721<space/></arg><arg name="doi">10.1098/rstl.1763.0033</arg></template></extension><space/><link><target>Felix Hoffmann</target></link>, a chemist at<space/><link><target>Bayer</target></link>, is credited with the synthesis of aspirin in 1897, though whether this was of his own initiative or under the direction of<space/><link><target>Arthur Eichengrn</target></link><space/>is controversial.<extension extension_name='ref' name="ReferenceA"><template><target>cite journal</target><arg name="last1"><space/>Sneader<space/></arg><arg name="first1"><space/>W.<space/></arg><arg name="title"><space/>The discovery of aspirin: A reappraisal<space/></arg><arg name="journal"><space/>BMJ (Clinical research ed.)<space/></arg><arg name="volume"><space/>321<space/></arg><arg name="issue"><space/>7276<space/></arg><arg name="pages"><space/>1591–1594<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>11124191<space/></arg><arg name="pmc"><space/>1119266<space/></arg><arg name="doi"><space/>10.1136/bmj.321.7276.1591<space/></arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="title">Acetylsalicylic acid<space/></arg><arg name="author">Schrör, Karsten<space/></arg><arg name="isbn">978-3-527-32109-4<space/></arg><arg name="year">2009<space/></arg><arg name="url">https://books.google.com/?id</arg><arg name="publisher">Wiley</arg></template></extension><space/>Aspirin is one of the most widely used medications in the world with an estimated 40,000<space/><link><target>tonnes</target></link><space/>of it being consumed each year.<extension extension_name='ref' name='cox3article'><template><target>Cite journal</target><arg name="title">Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?<space/></arg><arg name="journal">Proceedings of the National Academy of Sciences of the United States of America</arg><arg name="year">2002</arg><arg name="author2">Warner TD, Mitchell JA</arg><arg name="volume">99</arg><arg name="issue">21</arg><arg name="pages">13371–3</arg><arg name="pmid">12374850</arg><arg name="author">Warner, T. D.</arg><arg name="pmc">129677</arg><arg name="doi">10.1073/pnas.222543099</arg></template></extension><space/>In countries where &quot;Aspirin&quot; is a registered trademark owned by Bayer, the generic term is acetylsalicylic acid (ASA).<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.wordconstructions.com/articles/health/aspirin.html<space/></arg><arg name="title">The use of aspirin<space/></arg><arg name="publisher">Wordconstructions.com<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension><space/>It is on the<space/><link><target>WHO Model List of Essential Medicines</target></link>, the most important medications needed in a basic<space/><link><target>health system</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">WHO Model List of EssentialMedicines</arg><arg name="url">http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua</arg><arg name="work">World Health Organization</arg><arg name="accessdate">22 April 2014</arg><arg name="date">October 2013</arg></template></extension></preline></preblock><paragraph><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Medical use</heading><paragraph>Aspirin is used in the treatment of a number of conditions, including fever, pain,<space/><link><target>rheumatic fever</target></link>, and inflammatory diseases, such as<space/><link><target>rheumatoid arthritis</target></link>,<space/><link><target>pericarditis</target></link>, and<space/><link><target>Kawasaki disease</target></link>.<extension extension_name='ref' name="AHFS"><template><target>cite web</target><arg name="title">Aspirin</arg><arg name="url">http://www.drugs.com/monograph/aspirin.html</arg><arg name="work">The American Society of Health-System Pharmacists</arg><arg name="accessdate">3 April 2011</arg></template></extension><space/>Lower doses of aspirin have also shown to reduce the risk of death from a<space/><link><target>myocardial infarction</target><part>heart attack</part></link>, or the risk of<space/><link><target>stroke</target></link><space/>in some circumstances.<extension extension_name='ref' name="USFDA-patient-guideline"><template><target>cite web</target><arg name="title">Aspirin for Reducing Your Risk of Heart Attack and Stroke: Know the Facts</arg><arg name="url">http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/SafeDailyUseofAspirin/ucm291433.htm</arg><arg name="publisher">U.S. Food and Drug Administration</arg><arg name="accessdate">26 July 2012</arg></template></extension><extension extension_name='ref' name="USPSTF-CV"><template><target>cite web</target><arg name="title">Aspirin for the Prevention of Cardiovascular Disease</arg><arg name="url">http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm</arg><arg name="publisher">U.S. Preventive Services Task Force</arg><arg name="accessdate">26 July 2012</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Seshasai</arg><arg name="first1">SR</arg><arg name="author2">Wijesuriya, S; Sivakumaran, R; Nethercott, S; Erqou, S; Sattar, N; Ray, KK</arg><arg name="title">Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials</arg><arg name="journal">Archives of Internal Medicine</arg><arg name="date">13 February 2012</arg><arg name="volume">172</arg><arg name="issue">3</arg><arg name="pages">209–16</arg><arg name="pmid">22231610</arg><arg name="doi">10.1001/archinternmed.2011.628</arg></template></extension><space/>There is some evidence that aspirin is effective at preventing<space/><link><target>colorectal cancer</target></link>, though the mechanisms of this effect are unclear.<extension extension_name='ref' name="Algra 51827"><template><target>cite journal</target><arg name="last1">Algra</arg><arg name="first1">AM</arg><arg name="author2">Rothwell, PM</arg><arg name="title">Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials</arg><arg name="journal">The lancet oncology</arg><arg name="date">May 2012</arg><arg name="volume">13</arg><arg name="issue">5</arg><arg name="pages">518–27</arg><arg name="pmid">22440112</arg><arg name="doi">10.1016/S1470-2045(12)70112-2</arg></template></extension></paragraph><heading level='3'>Pain</heading><paragraph><link><target>File:Aspirin1.jpg</target><part>right</part><part>thumb</part><part>Aspirin 325 mg / 5 grains for pain</part></link><link><target>File:Aspirine macro shot.jpg</target><part>thumb</part><part>Uncoated aspirin<space/><link><target>Tablet (pharmacy)</target><part>tablets</part></link>, consisting of about 90% acetylsalicylic acid, along with a minor amount of inert fillers and binders</part></link>Aspirin is an effective analgesic for acute pain, but is generally considered inferior to<space/><link><target>ibuprofen</target></link><space/>for the alleviation of pain because aspirin is more likely to cause<space/><link><target>gastrointestinal bleeding</target></link>.<extension extension_name='ref' name="pmid15768621"><template><target>cite journal</target><arg name="last1"><space/>Sachs<space/></arg><arg name="first1"><space/>C. J.<space/></arg><arg name="title"><space/>Oral analgesics for acute nonspecific pain<space/></arg><arg name="journal"><space/>American family physician<space/></arg><arg name="volume"><space/>71<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>913–918<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15768621<space/></arg><arg name="url"><space/>http://www.aafp.org/afp/2005/0301/p913.html<space/></arg></template></extension><space/>Aspirin is generally ineffective for those pains caused by muscle<space/><link><target>cramp</target><trail>s</trail></link>,<space/><link><target>bloating</target></link>,<space/><link><target>gastric distension</target></link>, or acute skin irritation.<extension extension_name='ref' name="pmid14592563"><template><target>cite journal</target><arg name="title"><space/>The real dimension of analgesic activity of aspirin<space/></arg><arg name="journal"><space/>[[Thrombosis Research]]<space/></arg><arg name="volume"><space/>110<space/></arg><arg name="issue"><space/>5–6<space/></arg><arg name="pages"><space/>361–364<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14592563<space/></arg><arg name="doi"><space/>10.1016/j.thromres.2003.08.009<space/></arg><arg name="author1"><space/>Gaciong<space/></arg></template></extension><space/>As with other NSAIDs,<space/><link><target>Compound analgesic</target><part>combinations</part></link><space/>of aspirin and<space/><link><target>caffeine</target></link><space/>provide slightly greater pain relief than aspirin alone.<extension extension_name='ref' name="pmid22419343"><template><target>cite journal</target><arg name="last1"><space/>Derry<space/></arg><arg name="first1"><space/>C. J.<space/></arg><arg name="last2"><space/>Derry<space/></arg><arg name="first2"><space/>S.<space/></arg><arg name="last3"><space/>Moore<space/></arg><arg name="first3"><space/>R. A.<space/></arg><arg name="journal"><space/>Cochrane database of systematic reviews (Online)<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="pages"><space/>CD009281<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22419343<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1002/14651858.CD009281.pub2<space/></arg><arg name="title"><space/>Caffeine as an analgesic adjuvant for acute pain in adults<space/></arg><arg name="editor1-first"><space/>Sheena<space/></arg><arg name="editor1-last"><space/>Derry<space/></arg></template></extension><space/><link><target>Effervescent</target></link><space/>formulations of aspirin, such as<space/><link><target>Alka-Seltzer</target></link><space/>or Blowfish,<extension extension_name='ref' name="USFDA Blowfish"><template><target>cite web</target><arg name="title">BLOWFISH (aspirin, caffeine) tablet, effervescent [Rally Labs LLC]</arg><arg name="url">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid</arg><arg name="work">DailyMed</arg><arg name="publisher">U.S. Federal Drug Administration</arg><arg name="accessdate">27 July 2012</arg></template></extension><space/>relieve pain faster than aspirin in tablets,<extension extension_name='ref' name="pmid10868553"><template><target>cite journal</target><arg name="last1"><space/>Hersh<space/></arg><arg name="first1"><space/>E.<space/></arg><arg name="last2"><space/>Moore<space/></arg><arg name="first2"><space/>P.<space/></arg><arg name="last3"><space/>Ross<space/></arg><arg name="first3"><space/>G.<space/></arg><arg name="title"><space/>Over-the-counter analgesics and antipyretics: A critical assessment<space/></arg><arg name="journal"><space/>Clinical Therapeutics<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>500–548<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>10868553<space/></arg><arg name="doi"><space/>10.1016/S0149-2918(00)80043-0<space/></arg></template></extension><space/>which makes them useful for the treatment of<space/><link><target>migraine</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid18451718"><template><target>cite journal</target><arg name="last1"><space/>Mett<space/></arg><arg name="first1"><space/>A.<space/></arg><arg name="last2"><space/>Tfelt-Hansen<space/></arg><arg name="first2"><space/>P.<space/></arg><arg name="title"><space/>Acute migraine therapy: Recent evidence from randomized comparative trials<space/></arg><arg name="journal"><space/>Current Opinion in Neurology<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>331–337<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18451718<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1097/WCO.0b013e3282fee843<space/></arg></template></extension><space/><link><target>Topical medication</target><part>Topical</part></link><space/>aspirin may be effective for treating some types of<space/><link><target>neuropathic pain</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Kingery</arg><arg name="first">WS</arg><arg name="title">A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes</arg><arg name="journal">Pain</arg><arg name="date">November 1997</arg><arg name="volume">73</arg><arg name="issue">2</arg><arg name="pages">123–39</arg><arg name="pmid">9415498</arg><arg name="doi">10.1016/S0304-3959(97)00049-3</arg></template></extension></paragraph><heading level='4'>Headache</heading><paragraph>Aspirin, either by itself or in a combined formulation, effectively treats some<space/><link><target>Headache#Classification</target><part>types of headache</part></link>, but its efficacy may be questionable for others. Secondary headaches, meaning those caused by another disorder or trauma, should be promptly treated by a medical provider.</paragraph><paragraph>Among primary headaches, the<space/><link><target>International Classification of Headache Disorders</target></link><space/>distinguishes between<space/><link><target>tension headache</target></link><space/>(the most common), migraine, and<space/><link><target>cluster headache</target></link>. Aspirin or other over-the-counter analgesics are widely recognized as effective for the treatment of tension headache.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Loder</arg><arg name="first1">E</arg><arg name="author2">Rizzoli, P</arg><arg name="title">Tension-type headache</arg><arg name="journal">BMJ (Clinical research ed.)</arg><arg name="date">12 January 2008<space/></arg><arg name="volume">336<space/></arg><arg name="issue">7635<space/></arg><arg name="pages">88–92<space/></arg><arg name="pmid">18187725<space/></arg><arg name="doi">10.1136/bmj.39412.705868.AD</arg><arg name="pmc">2190284</arg></template></extension>Aspirin, especially as a component of an acetaminophen/aspirin/caffeine formulation,<space/><italics>e.g.</italics>,<space/><link><target>Excedrin</target></link><space/>Migraine, is considered a first-line therapy in the treatment of migraine, and comparable to lower doses of<space/><link><target>sumatriptan</target></link>. It is most effective at stopping migraines when they are first beginning.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Gilmore</arg><arg name="first1">B</arg><arg name="author2">Michael, M</arg><arg name="title">Treatment of acute migraine headache</arg><arg name="journal">American family physician</arg><arg name="date">1 February 2011</arg><arg name="volume">83</arg><arg name="issue">3</arg><arg name="pages">271–80</arg><arg name="pmid">21302868</arg></template></extension></paragraph><heading level='3'>Fever</heading><paragraph>Like its ability to control pain, aspirin's ability to control<space/><link><target>fever</target></link><space/>is due to its action on the<space/><link><target>prostaglandin</target></link><space/>system through its irreversible inhibition of<space/><link><target>COX</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Bartfai</arg><arg name="first1">T</arg><arg name="author2">Conti, B</arg><arg name="title">Fever</arg><arg name="journal">TheScientificWorldJournal</arg><arg name="date">16 March 2010</arg><arg name="volume">10</arg><arg name="pages">490–503</arg><arg name="doi">10.1100/tsw.2010.50</arg><arg name="pmid">20305990</arg><arg name="pmc">2850202</arg></template></extension><space/>Although aspirin's use as an<space/><link><target>antipyretic</target></link><space/>in adults is well-established, many medical societies and regulatory agencies (including the<space/><link><target>American Academy of Family Physicians</target></link>, the<space/><link><target>American Academy of Pediatrics</target></link>, and the U.S.<space/><link><target>Food and Drug Administration</target></link><space/>(FDA)) strongly advise against using aspirin for treatment of fever in children because of the risk of<space/><link><target>Reye's syndrome</target></link>, a rare but often fatal illness associated with the use of aspirin or other salicylates in children during episodes of viral or bacterial infection.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Pugliese</arg><arg name="first1">A</arg><arg name="author2">Beltramo, T; Torre, D</arg><arg name="title">Reye's and Reye's-like syndromes</arg><arg name="journal">Cell biochemistry and function</arg><arg name="date">October 2008</arg><arg name="volume">26</arg><arg name="issue">7</arg><arg name="pages">741–6</arg><arg name="pmid">18711704</arg><arg name="doi">10.1002/cbf.1465</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Beutler</arg><arg name="first1">AI</arg><arg name="author2">Chesnut, GT; Mattingly, JC; Jamieson, B</arg><arg name="title">FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes</arg><arg name="journal">American family physician</arg><arg name="date">15 December 2009</arg><arg name="volume">80</arg><arg name="issue">12</arg><arg name="page">1472</arg><arg name="pmid">20000310</arg></template></extension><extension extension_name='ref' name="AAPweb"><template><target>cite web</target><arg name="title">Medications Used to Treat Fever</arg><arg name="url">http://www.healthychildren.org/English/health-issues/conditions/fever/Pages/Medications-Used-to-Treat-Fever.aspx</arg><arg name="publisher">American Academy of Pediatrics</arg><arg name="accessdate">25 November 2012</arg></template></extension><space/>Because of the risk of Reye's syndrome in children, in 1986, the FDA required labeling on all aspirin-containing medications advising against its use in children and teenagers.<extension extension_name='ref' name="FDA 1986 FR"><template><target>cite journal</target><arg name="title">51 FR 8180</arg><arg name="url">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/UCM078593.pdf</arg><arg name="journal">United States Federal Register</arg><arg name="volume">51</arg><arg name="issue">45</arg><arg name="date">7 March 1986</arg><arg name="accessdate">25 November 2012</arg></template></extension></paragraph><heading level='3'>Swelling and inflammation</heading><paragraph>Aspirin is used as an anti-inflammatory agent for both acute and long-term inflammation,<extension extension_name='ref'>Thea Morris, Melanie Stables, Adrian Hobbs, Patricia de Souza, Paul Colville-Nash, Tim Warner, Justine Newson, Geoffrey Bellingan, and Derek W. Gilroy,<space/><link type='external' href='http://www.jimmunol.org/content/183/3/2089.full.pdf'>&quot;Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans&quot;</link>,<space/><italics>J. Immunology</italics>, 183: 2089-2096, 2009 (accessed Aug 29, 2014)</extension><space/>as well as for treatment of inflammatory diseases, such as rheumatoid arthritis.<extension extension_name='ref' name="AHFS"></extension></paragraph><heading level='3'>Heart attacks and strokes</heading><paragraph>Aspirin is an important part of treatment of those who have had a<space/><link><target>myocardial infarction</target></link><space/>(heart attack).<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Myocardial Infarction with ST-Segment Elevation: The Acute Management of Myocardial Infarction with ST-Segment Elevation [Internet]. NICE Clinical Guidelines, No. 167.</arg><arg name="date">July 2013</arg><arg name="page">17.2</arg><arg name="url">http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071000/#</arg></template></extension><space/>One trial found that among those likely having a<space/><link><target>ST-segment elevation MI</target></link>, aspirin saves the life of 1 in 42 by reducing the 30-day death rate from 11.8% to 9.4%.<extension extension_name='ref' name="Qu2009"></extension><space/>There was no difference in major bleeding (need for blood transfusion or brain bleeding), but there was a small increase in minor bleeding amounting to roughly 1 in every 167 people given aspirin.<extension extension_name='ref' name="Qu2009"><template><target>cite web</target><arg name="last1">Quaas</arg><arg name="first1">Joshua</arg><arg name="title">Aspirin Given Immediately for a Major Heart Attack (STEMI)</arg><arg name="url">http://www.thennt.com/nnt/aspirin-for-major-heart-attack/</arg><arg name="accessdate">15 October 2015</arg><arg name="date">November 28, 2009</arg></template></extension></paragraph><paragraph>For a subset of the people, aspirin may help<space/><link><target>Preventive medicine</target><part>prevent</part></link><space/>heart attacks and strokes. In lower doses, aspirin prevents the progression of cardiovascular disease, and reduce the frequency of these events for those with a history of them.<extension extension_name='ref' name="pmid20112887"><template><target>cite journal</target><arg name="last1">Hall</arg><arg name="first1">SL</arg><arg name="author2">Lorenc, T</arg><arg name="title">Secondary prevention of coronary artery disease</arg><arg name="journal">American family physician</arg><arg name="date">1 February 2010</arg><arg name="volume">81</arg><arg name="issue">3</arg><arg name="pages">289–96</arg><arg name="pmid">20112887</arg></template></extension><extension extension_name='ref' name="pmid19482214"><template><target>cite journal</target><arg name="last1">Baigent<space/></arg><arg name="first1">C<space/></arg><arg name="last2">Blackwell<space/></arg><arg name="first2">L<space/></arg><arg name="last3">Collins<space/></arg><arg name="first3">R<space/></arg><arg name="last4">Emberson<space/></arg><arg name="first4">J<space/></arg><arg name="last5">Godwin<space/></arg><arg name="first5">J<space/></arg><arg name="last6">Peto<space/></arg><arg name="first6">R<space/></arg><arg name="last7">Buring<space/></arg><arg name="first7">J<space/></arg><arg name="last8">Hennekens<space/></arg><arg name="first8">C<space/></arg><arg name="last9">Kearney<space/></arg><arg name="first9">P<space/></arg><arg name="last10">Meade<space/></arg><arg name="first10">T<space/></arg><arg name="last11">Patrono<space/></arg><arg name="first11">C<space/></arg><arg name="last12">Roncaglioni<space/></arg><arg name="first12">MC<space/></arg><arg name="last13">Zanchetti<space/></arg><arg name="first13">A<space/></arg><arg name="title">Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials<space/></arg><arg name="journal">Lancet<space/></arg><arg name="volume">373<space/></arg><arg name="issue">9678<space/></arg><arg name="pages">1849–60<space/></arg><arg name="year">2009<space/></arg><arg name="pmid">19482214<space/></arg><arg name="pmc">2715005<space/></arg><arg name="doi">10.1016/S0140-6736(09)60503-1</arg></template></extension><space/>People in their 50s benefit most from daily low-dose aspirin as a preventive measure against heart disease.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.drugs.com/news/their-50s-benefit-most-low-aspirin-report-says-58263.html<space/></arg><arg name="title">People in Their 50s Benefit Most From Low-Dose Aspirin, Report Says<space/></arg><arg name="accessdate">24 September 2015</arg></template></extension></paragraph><paragraph>Aspirin appears to offer little benefit to those at lower risk of heart attack or strokefor instance, those without a history of these events or with pre-existing disease. Some studies recommend aspirin on a case-by-case basis,<extension extension_name='ref' name="pmid19293073"><template><target>cite journal</target><arg name="last1">Wolff</arg><arg name="first1">T</arg><arg name="author2">Miller, T; Ko, S</arg><arg name="title">Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force</arg><arg name="journal">Annals of Internal Medicine</arg><arg name="date">17 March 2009</arg><arg name="volume">150</arg><arg name="issue">6</arg><arg name="pages">405–10</arg><arg name="pmid">19293073</arg><arg name="doi">10.7326/0003-4819-150-6-200903170-00009</arg></template></extension><extension extension_name='ref' name="USPSTF aspirin"><template><target>cite web</target><arg name="last">U.S. Preventive Services Task Force</arg><arg name="title">Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement</arg><arg name="url">http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm</arg><arg name="accessdate">15 August 2012</arg></template></extension><space/>while others have suggested the risks of other events, such as gastrointestinal bleeding, were enough to outweigh any potential benefit, and recommended against using aspirin for primary prevention entirely.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Berger</arg><arg name="first1">JS</arg><arg name="author2">Lala, A, Krantz, MJ, Baker, GS, Hiatt, WR</arg><arg name="title">Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials</arg><arg name="journal">American heart journal</arg><arg name="date">July 2011</arg><arg name="volume">162</arg><arg name="issue">1</arg><arg name="pages">115–24.e2</arg><arg name="pmid">21742097</arg><arg name="doi">10.1016/j.ahj.2011.04.006</arg></template></extension><space/>Aspirin has also been suggested as a component of a<space/><link><target>polypill</target></link><space/>for prevention of cardiovascular disease.<extension extension_name='ref' name="pmid16100022"><template><target>cite journal</target><arg name="last">Norris</arg><arg name="first">JW</arg><arg name="title">Antiplatelet agents in secondary prevention of stroke: a perspective</arg><arg name="journal">Stroke; a journal of cerebral circulation</arg><arg name="date">September 2005</arg><arg name="volume">36</arg><arg name="issue">9</arg><arg name="pages">2034–6</arg><arg name="pmid">16100022</arg><arg name="doi">10.1161/01.STR.0000177887.14339.46</arg></template></extension><extension extension_name='ref' name="pmid16603580"><template><target>cite journal</target><arg name="last1">Sleight</arg><arg name="first1">P</arg><arg name="author2">Pouleur, H; Zannad, F</arg><arg name="title">Benefits, challenges, and registerability of the polypill</arg><arg name="journal">European heart journal</arg><arg name="date">July 2006</arg><arg name="volume">27</arg><arg name="issue">14</arg><arg name="pages">1651–6</arg><arg name="pmid">16603580</arg><arg name="doi">10.1093/eurheartj/ehi841</arg></template></extension></paragraph><paragraph>Complicating the use of aspirin for prevention is the phenomenon of aspirin resistance.<extension extension_name='ref' name="pmid16364973"><template><target>cite journal</target><arg name="last1">Wang</arg><arg name="first1">TH</arg><arg name="author2">Bhatt, DL; Topol, EJ</arg><arg name="title">Aspirin and clopidogrel resistance: an emerging clinical entity</arg><arg name="journal">European heart journal</arg><arg name="date">March 2006</arg><arg name="volume">27</arg><arg name="issue">6</arg><arg name="pages">647–54</arg><arg name="pmid">16364973</arg><arg name="doi">10.1093/eurheartj/ehi684</arg></template></extension><extension extension_name='ref' name="pmid20944898"><template><target>cite journal</target><arg name="last1">Oliveira</arg><arg name="first1">DC</arg><arg name="author2">Silva, RF; Silva, DJ; Lima, VC</arg><arg name="title">Aspirin resistance: fact or fiction?</arg><arg name="journal">Arquivos brasileiros de cardiologia</arg><arg name="date">September 2010</arg><arg name="volume">95</arg><arg name="issue">3</arg><arg name="pages">e91–4</arg><arg name="pmid">20944898</arg><arg name="doi">10.1590/S0066-782X2010001300024</arg></template></extension><space/>For people who are resistant, aspirin's efficacy is reduced.<extension extension_name='ref' name="pmid21306212"><template><target>cite journal</target><arg name="last1">Topçuoglu</arg><arg name="first1">MA</arg><arg name="author2">Arsava, EM; Ay, H</arg><arg name="title">Antiplatelet resistance in stroke</arg><arg name="journal">Expert Review of Neurotherapeutics</arg><arg name="date">February 2011</arg><arg name="volume">11</arg><arg name="issue">2</arg><arg name="pages">251–63</arg><arg name="pmid">21306212</arg><arg name="doi">10.1586/ern.10.203</arg><arg name="pmc">3086673</arg></template></extension><space/>Some authors have suggested testing regimens to identify people who are resistant to aspirin or other antithrombotic drugs (such as<space/><link><target>clopidogrel</target></link>).<extension extension_name='ref' name="pmid19576352"><template><target>cite journal</target><arg name="last1">Ben-Dor</arg><arg name="first1">I</arg><arg name="author2">Kleiman, NS; Lev, E</arg><arg name="title">Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy</arg><arg name="journal">The American journal of cardiology</arg><arg name="date">15 July 2009</arg><arg name="volume">104</arg><arg name="issue">2</arg><arg name="pages">227–33</arg><arg name="pmid">19576352</arg><arg name="doi">10.1016/j.amjcard.2009.03.022</arg></template></extension></paragraph><heading level='3'>After surgery</heading><paragraph>After<space/><link><target>percutaneous coronary intervention</target><trail>s</trail></link><space/>(PCIs), such as the placement of a<space/><link><target>coronary artery</target></link><space/><link><target>stent</target></link>, a U.S.<space/><link><target>Agency for Healthcare Research and Quality</target></link><space/>guideline recommends that aspirin be taken indefinitely.<extension extension_name='ref'><template><target>cite web</target><arg name="last">National Guideline Clearinghouse (NGC)</arg><arg name="title">2011 ACCF/AHA/SCAI guideline for percutaneous coronary artery intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.</arg><arg name="url">http://www.guideline.gov/content.aspx?id</arg><arg name="publisher">United States Agency for Healthcare Research and Quality (AHRQ)</arg><arg name="accessdate">28 August 2012</arg></template></extension><space/>Frequently, aspirin is combined with an<space/><link><target>ADP receptor inhibitor</target></link>, such as<space/><link><target>clopidogrel</target></link>,<space/><link><target>prasugrel</target></link>, or<space/><link><target>ticagrelor</target></link><space/>to prevent<space/><link><target>thrombosis</target><part>blood clots</part></link>. This is called dual antiplatelet therapy (DAPT). United States and European Union guidelines disagree somewhat about how long, and for what indications this combined therapy should be continued after surgery. U.S. guidelines recommend DAPT for at least 12 months, while EU guidelines recommend DAPT for 612 months after a drug-eluting stent placement.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Musumeci</arg><arg name="first1">G</arg><arg name="author2">Di Lorenzo, E; Valgimigli, M</arg><arg name="title">Dual antiplatelet therapy duration: what are the drivers?</arg><arg name="journal">Current Opinion in Cardiology</arg><arg name="date">December 2011</arg><arg name="volume">26 Suppl 1</arg><arg name="pages">S4–14</arg><arg name="pmid">22129582</arg><arg name="doi">10.1097/01.hco.0000409959.11246.ba</arg></template></extension><space/>However, they agree that aspirin be continued indefinitely after DAPT is complete.</paragraph><heading level='3'>Cancer prevention</heading><paragraph>Aspirin reduces the overall risk of both getting cancer and dying from cancer.<extension extension_name='ref' name="Cuz2014"><template><target>cite journal</target><arg name="last1">Cuzick</arg><arg name="first1">J</arg><arg name="last2">Thorat</arg><arg name="first2">MA</arg><arg name="last3">Bosetti</arg><arg name="first3">C</arg><arg name="last4">Brown</arg><arg name="first4">PH</arg><arg name="last5">Burn</arg><arg name="first5">J</arg><arg name="last6">Cook</arg><arg name="first6">NR</arg><arg name="last7">Ford</arg><arg name="first7">LG</arg><arg name="last8">Jacobs</arg><arg name="first8">EJ</arg><arg name="last9">Jankowski</arg><arg name="first9">JA</arg><arg name="last10">La Vecchia</arg><arg name="first10">C</arg><arg name="last11">Law</arg><arg name="first11">M</arg><arg name="last12">Meyskens</arg><arg name="first12">F</arg><arg name="last13">Rothwell</arg><arg name="first13">PM</arg><arg name="last14">Senn</arg><arg name="first14">HJ</arg><arg name="last15">Umar</arg><arg name="first15">A</arg><arg name="title">Estimates of benefits and harms of prophylactic use of aspirin in the general population.</arg><arg name="journal">Annals of Oncology<space/></arg><arg name="date">Aug 5, 2014</arg><arg name="pmid">25096604</arg><arg name="doi">10.1093/annonc/mdu225</arg><arg name="volume">26</arg><arg name="pages">47–57</arg></template></extension><space/>This effect is particularly beneficial for<space/><link><target>colorectal cancer</target></link><space/>(CRC).<extension extension_name='ref' name="Algra 51827"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Manzano</arg><arg name="first1">A</arg><arg name="author2">Pérez-Segura, P</arg><arg name="title">Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?</arg><arg name="journal">TheScientificWorldJournal</arg><arg name="year">2012</arg><arg name="volume">2012</arg><arg name="page">327341</arg><arg name="doi">10.1100/2012/327341</arg><arg name="pmid">22649288</arg><arg name="pmc">3353298</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Chan</arg><arg name="first1">AT</arg><arg name="author2">Arber, N; Burn, J; Chia, WK; Elwood, P; Hull, MA; Logan, RF; Rothwell, PM; Schrör, K; Baron, JA</arg><arg name="title">Aspirin in the chemoprevention of colorectal neoplasia: an overview</arg><arg name="journal">Cancer prevention research (Philadelphia, Pa.)</arg><arg name="date">February 2012</arg><arg name="volume">5</arg><arg name="issue">2</arg><arg name="pages">164–78</arg><arg name="pmid">22084361</arg><arg name="doi">10.1158/1940-6207.CAPR-11-0391</arg><arg name="pmc">3273592</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Thun</arg><arg name="first1">MJ</arg><arg name="author2">Jacobs, EJ; Patrono, C</arg><arg name="title">The role of aspirin in cancer prevention</arg><arg name="journal">Nature Reviews Clinical Oncology</arg><arg name="date">3 April 2012</arg><arg name="volume">9</arg><arg name="issue">5</arg><arg name="pages">259–67</arg><arg name="pmid">22473097</arg><arg name="doi">10.1038/nrclinonc.2011.199</arg></template></extension></paragraph><paragraph>Some conclude the benefits are greater than the risks due to bleeding in those at average risk.<extension extension_name='ref' name="Cuz2014"></extension><space/>Other are unclear if the benefits are greater than the risk.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Sutcliffe</arg><arg name="first1">P</arg><arg name="last2">Connock</arg><arg name="first2">M</arg><arg name="last3">Gurung</arg><arg name="first3">T</arg><arg name="last4">Freeman</arg><arg name="first4">K</arg><arg name="last5">Johnson</arg><arg name="first5">S</arg><arg name="last6">Kandala</arg><arg name="first6">NB</arg><arg name="last7">Grove</arg><arg name="first7">A</arg><arg name="last8">Gurung</arg><arg name="first8">B</arg><arg name="last9">Morrow</arg><arg name="first9">S</arg><arg name="last10">Clarke</arg><arg name="first10">A</arg><arg name="title">Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.</arg><arg name="journal">Health technology assessment (Winchester, England)</arg><arg name="date">Sep 2013</arg><arg name="volume">17</arg><arg name="issue">43</arg><arg name="pages">1–253</arg><arg name="pmid">24074752</arg><arg name="doi">10.3310/hta17430</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kim</arg><arg name="first1">SE</arg><arg name="title">The benefit-risk consideration in long-term use of alternate-day, low dose aspirin: focus on colorectal cancer prevention.</arg><arg name="journal">Annals of Gastroenterology<space/></arg><arg name="date">2014</arg><arg name="volume">27</arg><arg name="issue">1</arg><arg name="pages">87–88</arg><arg name="pmid">24714632</arg></template></extension><space/>Given this uncertainty, the 2007<space/><link><target>United States Preventive Services Task Force</target></link><space/>guidelines on this topic recommended against the use of aspirin for prevention of CRC in people with average risk.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">U.S. Preventive Services Task</arg><arg name="first">Force</arg><arg name="title">Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement</arg><arg name="journal">Annals of Internal Medicine</arg><arg name="date">6 March 2007</arg><arg name="volume">146</arg><arg name="issue">5</arg><arg name="pages">361–4</arg><arg name="pmid">17339621</arg><arg name="doi">10.7326/0003-4819-146-5-200703060-00008</arg></template></extension></paragraph><heading level='3'>Other uses</heading><paragraph>Aspirin is a first-line treatment for the fever and joint-pain symptoms of<space/><link><target>rheumatic fever</target><part>acute rheumatic fever</part></link>. The therapy often lasts for one to two weeks, and is rarely indicated for longer periods. After fever and pain have subsided, the aspirin is no longer necessary, since it does not decrease the incidence of heart complications and residual rheumatic heart disease.<extension extension_name='ref' name="NHFA"><template><target>cite web</target><arg name="url">http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/DiagnosisandmanagementofacuterheumaticfeverandrheumaticheartdiseaseinAustralia/NHFA-CSANZ_ARF_RHD_2006.pdf</arg><arg name="archiveurl">https://web.archive.org/web/20080726052030/http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/DiagnosisandmanagementofacuterheumaticfeverandrheumaticheartdiseaseinAustralia/NHFA-CSANZ_ARF_RHD_2006.pdf</arg><arg name="archivedate">2008-07-26</arg><arg name="title">Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review<space/></arg><arg name="author">National Heart Foundation of Australia (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand<space/></arg><arg name="year">2006<space/></arg><arg name="format">PDF<space/></arg><arg name="publisher">National Heart Foundation of Australia<space/></arg><arg name="pages">33–37<space/></arg><arg name="accessdate">9 May 2011</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Working Group on Pediatric Acute Rheumatic Fever and Cardiology Chapter of Indian Academy of<space/></arg><arg name="first1">Pediatrics</arg><arg name="author2">Saxena, A; Kumar, RK; Gera, RP; Radhakrishnan, S; Mishra, S; Ahmed, Z</arg><arg name="title">Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease</arg><arg name="journal">Indian pediatrics</arg><arg name="date">July 2008</arg><arg name="volume">45</arg><arg name="issue">7</arg><arg name="pages">565–73</arg><arg name="pmid">18695275</arg></template></extension><space/><link><target>Naproxen</target></link><space/>has been shown to be as effective as aspirin and less toxic, but due to the limited clinical experience, naproxen is recommended only as a second-line treatment.<extension extension_name='ref' name="NHFA"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last2"><space/>Tauber<space/></arg><arg name="first2"><space/>T.<space/></arg><arg name="last3"><space/>Somekh<space/></arg><arg name="first3"><space/>E.<space/></arg><arg name="last4"><space/>Brik<space/></arg><arg name="first4"><space/>R.<space/></arg><arg name="last5"><space/>Barash<space/></arg><arg name="first5"><space/>J.<space/></arg><arg name="last6"><space/>Mukamel<space/></arg><arg name="first6"><space/>M.<space/></arg><arg name="last7"><space/>Harel<space/></arg><arg name="first7"><space/>L.<space/></arg><arg name="last8"><space/>Lorber<space/></arg><arg name="first8"><space/>A.<space/></arg><arg name="last9"><space/>Berkovitch<space/></arg><arg name="first9"><space/>M.<space/></arg><arg name="last10"><space/>Uziel<space/></arg><arg name="first10"><space/>Y.<space/></arg><arg name="title"><space/>Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial<space/></arg><arg name="journal"><space/>The Journal of pediatrics<space/></arg><arg name="volume"><space/>143<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>399–401<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14517527<space/></arg><arg name="doi"><space/>10.1067/S0022-3476(03)00388-3<space/></arg><arg name="author11"><space/>Pediatric Rheumatlogy Study Group of Israel<space/></arg><arg name="author1"><space/>Hashkes<space/></arg></template></extension></paragraph><paragraph>Along with rheumatic fever,<space/><link><target>Kawasaki disease</target></link><space/>remains one of the few indications for aspirin use in children<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Rowley</arg><arg name="first1">AH</arg><arg name="author2">Shulman, ST</arg><arg name="title">Pathogenesis and management of Kawasaki disease</arg><arg name="journal">Expert review of anti-infective therapy</arg><arg name="date">February 2010</arg><arg name="volume">8</arg><arg name="issue">2</arg><arg name="pages">197–203</arg><arg name="pmid">20109049</arg><arg name="doi">10.1586/eri.09.109</arg><arg name="pmc">2845298</arg></template></extension><space/>in spite of a lack of high quality evidence for its effectiveness.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Baumer</arg><arg name="first1">JH</arg><arg name="author2">Love, SJ; Gupta, A; Haines, LC; Maconochie, I; Dua, JS</arg><arg name="title">Salicylate for the treatment of Kawasaki disease in children</arg><arg name="journal">Cochrane Database of Systematic Reviews</arg><arg name="date">18 October 2006</arg><arg name="issue">4</arg><arg name="pages">CD004175</arg><arg name="pmid">17054199</arg><arg name="doi">10.1002/14651858.CD004175.pub2</arg><arg name="editor1-last">Baumer</arg><arg name="editor1-first">J Harry</arg></template></extension></paragraph><paragraph>Low-dose aspirin supplementation has moderate benefits when used for prevention of<space/><link><target>pre-eclampsia</target></link>.<extension extension_name='ref' name="Duley_2007"><template><target>cite journal</target><arg name="last1"><space/>Duley<space/></arg><arg name="first1"><space/>L.<space/></arg><arg name="last2"><space/>Henderson-Smart<space/></arg><arg name="first2"><space/>D. J.<space/></arg><arg name="last3"><space/>Meher<space/></arg><arg name="first3"><space/>S.<space/></arg><arg name="last4"><space/>King<space/></arg><arg name="first4"><space/>J. F.<space/></arg><arg name="journal"><space/>Cochrane database of systematic reviews (Online)<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>CD004659<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17443552<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1002/14651858.CD004659.pub2<space/></arg><arg name="title"><space/>Antiplatelet agents for preventing pre-eclampsia and its complications<space/></arg><arg name="editor1-first"><space/>Lelia<space/></arg><arg name="editor1-last"><space/>Duley<space/></arg></template></extension><extension extension_name='ref' name="Roberge_2012"><template><target>cite journal</target><arg name="last1"><space/>Roberge<space/></arg><arg name="first1"><space/>S. P.<space/></arg><arg name="last2"><space/>Villa<space/></arg><arg name="first2"><space/>P.<space/></arg><arg name="last3"><space/>Nicolaides<space/></arg><arg name="first3"><space/>K.<space/></arg><arg name="last4"><space/>Giguère<space/></arg><arg name="first4"><space/>Y.<space/></arg><arg name="last5"><space/>Vainio<space/></arg><arg name="first5"><space/>M.<space/></arg><arg name="last6"><space/>Bakthi<space/></arg><arg name="first6"><space/>A.<space/></arg><arg name="last7"><space/>Ebrashy<space/></arg><arg name="first7"><space/>A.<space/></arg><arg name="last8"><space/>Bujold<space/></arg><arg name="first8"><space/>E.<space/></arg><arg name="title"><space/>Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis<space/></arg><arg name="journal"><space/>Fetal Diagnosis and Therapy<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>141–146<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22441437<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1159/000336662<space/></arg></template></extension></paragraph><heading level='3'>Resistance</heading><paragraph>For some people, aspirin does not have as strong an effect on platelets as for others, an effect known as aspirin resistance or insensitivity. One study has suggested women are more likely to be resistant than men,<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS<space/></arg><arg name="title">Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction<space/></arg><arg name="journal">Annals of Pharmacotherapy<space/></arg><arg name="volume"><space/>41</arg><arg name="issue">May<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17456544</arg><arg name="doi">10.1345/aph.1H621</arg><arg name="pages">737–41</arg></template></extension><space/>and a different, aggregate study of 2,930 patients found 28% were resistant.<extension extension_name='ref' name="pmid18202034"><template><target>Cite journal</target><arg name="author">Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR<space/></arg><arg name="title">Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis<space/></arg><arg name="journal">BMJ<space/></arg><arg name="volume">336<space/></arg><arg name="issue">7637<space/></arg><arg name="pages">195–8<space/></arg><arg name="year">2008<space/></arg><arg name="pmid">18202034<space/></arg><arg name="pmc">2213873</arg><arg name="doi">10.1136/bmj.39430.529549.BE</arg></template></extension>A study in 100 Italian patients, though, found, of the apparent 31% aspirin-resistant subjects, only 5% were truly resistant, and the others were<space/><link><target>Compliance (medicine)</target><part>noncompliant</part></link>.<extension extension_name='ref' name="pmid18680540"><template><target>Cite journal</target><arg name="author">Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F</arg><arg name="title">Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance<space/></arg><arg name="journal">J. Thromb. Haemost.</arg><arg name="volume">6<space/></arg><arg name="issue">10<space/></arg><arg name="pages">1832–4<space/></arg><arg name="year">2008<space/></arg><arg name="pmid">18680540<space/></arg><arg name="doi">10.1111/j.1538-7836.2008.03122.x</arg></template></extension>Another study of 400 healthy volunteers found no subjects who were truly resistant, but some had &quot;pseudoresistance, reflecting delayed and reduced drug absorption&quot;.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1161/CIRCULATIONAHA.112.117283</arg><arg name="journal">Circulation</arg><arg name="title">Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin</arg><arg name="laysummary">http://www.nytimes.com/2012/12/05/business/coating-on-buffered-aspirin-may-hide-its-heart-protective-effects.html?</arg><arg name="publication-date">4 December 2012</arg><arg name="laysource">The New York Times</arg><arg name="laydate">4 December 2012</arg><arg name="author">Tilo Grosser, Susanne Fries, John A. Lawson, Shiv C. Kapoor, Gregory R. Grant and Garret A. FitzGerald</arg><arg name="pmid">23212718</arg><arg name="year">2013</arg><arg name="volume">127</arg><arg name="issue">3</arg><arg name="pages">377–85</arg><arg name="pmc">3552520</arg></template></extension></paragraph><preblock><preline></preline></preblock><heading level='3'>Dosage</heading><paragraph><link><target>File:Regular strength enteric coated aspirin tablets.jpg</target><part>thumb</part><part>Coated 325-mg (5-grain) aspirin tablets</part></link><link><target>Image:5 grain aspirin.jpg</target><part>thumb</part><part>250px</part><part>The 5-grain aspirin. The usage guidance label on a bottle of aspirin indicates that the dosage is &quot;325&amp;nbsp;mg (5&amp;nbsp;gr)&quot;.</part></link>Adult aspirin tablets are produced in standardised sizes, which vary slightly from country to country, for example 300&amp;nbsp;mg in Britain and 325&amp;nbsp;mg (or 5<space/><link><target>Grain (unit)</target><part>grains</part></link>) in the United States. Smaller doses are based on these standards,<space/><italics>e.g.</italics>, 75-mg and 81-mg tablets. The 81-mg (1<template><target>frac</target><arg>4</arg></template>-grain) tablets are commonly called &quot;baby aspirin&quot; or &quot;baby-strength&quot;, because they were originallybut no longerintended to be administered to infants and children.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>Invention of the Safety Cap</arg><arg name="url"><space/>http://digitaldukemed.mc.duke.edu/pcc/safety_cap.html</arg><arg name="website"><space/>digitaldukemed.mc.duke.edu</arg><arg name="accessdate"><space/>2015-09-04</arg></template></extension><space/>No medical significance occurs due to the slight difference in dosage between the 75-mg and the 81-mg tablets.</paragraph><paragraph>In general, for adults, doses are taken four times a day for fever or arthritis,<extension extension_name='ref' name="BNF"><template><target>Cite book</target><arg name="title">[[British National Formulary]]</arg><arg name="edition">45</arg><arg name="year">2003</arg><arg name="publisher"><space/>[[British Medical Journal]] and [[Royal Pharmaceutical Society of Great Britain]]</arg></template></extension><space/>with doses near the maximal daily dose used historically for the treatment of rheumatic fever.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.medscape.com/druginfo/monograph?cid</arg><arg name="title">Aspirin monograph: dosages, etc<space/></arg><arg name="publisher">Medscape.com<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension><space/>For the prevention of myocardial infarction (MI) in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.<extension extension_name='ref' name="BNF"></extension></paragraph><paragraph>Recommendations from the USPSTF<extension extension_name='ref'>(USPSTF, March 2009)</extension><space/>on the use of aspirin for the primary prevention of coronary heart disease encourage men aged 4579 and women aged 5579 to use aspirin when the potential benefit of a reduction in MI for men or stroke for women outweighs the potential harm of an increase in gastrointestinal hemorrhage.<extension extension_name='ref' name="medscape"><template><target>cite web</target><arg name="url">http://cme.medscape.com/viewarticle/589895?src</arg><arg name="title">Aspirin: More Evidence That Low Dose Is All That Is Needed (from Medscape)<space/></arg><arg name="publisher">Cme.medscape.com<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension><space/>The WHI study said regular low-dose (75- or 81-mg) aspirin female users had a 25% lower risk of death from cardiovascular disease and a 14% lower risk of death from any cause.<extension extension_name='ref' name="medscape"></extension><space/>Low-dose aspirin use was also associated with a trend toward lower risk of cardiovascular events, and lower aspirin doses (75 or 81&amp;nbsp;mg/day) may optimize efficacy and safety for patients requiring aspirin for long-term prevention.<extension extension_name='ref' name="medscape"></extension></paragraph><paragraph>In children with Kawasaki disease, aspirin is taken at dosages based on body weight, initially four times a day for up to two weeks and then at a lower dose once daily for a further six to eight weeks.<extension extension_name='ref'><template><target>Cite book</target><arg name="title">[[British National Formulary for Children]]</arg><arg name="year">2006</arg><arg name="publisher"><space/>[[British Medical Journal]] and [[Royal Pharmaceutical Society]]</arg></template></extension></paragraph><heading level='2'>Adverse effects</heading><heading level='3'>Contraindications</heading><preblock><preline>Aspirin should not be taken by people who are allergic to<space/><link><target>ibuprofen</target></link><space/>or<space/><link><target>naproxen</target></link>,<extension extension_name='ref' name="drugs.com"></extension><extension extension_name='ref' name="personalmd"></extension><space/>or who have<space/><link><target>salicylate intolerance</target></link><extension extension_name='ref' name="pmid16247191"><template><target>Cite journal</target><arg name="last1">Raithel<space/></arg><arg name="first1">M.<space/></arg><arg name="last2">Baenkler<space/></arg><arg name="first2">H. W.<space/></arg><arg name="last3">Naegel<space/></arg><arg name="first3">A.<space/></arg><arg name="last4">Buchwald<space/></arg><arg name="first4">F.<space/></arg><arg name="last5">Schultis<space/></arg><arg name="first5">H. W.<space/></arg><arg name="last6">Backhaus<space/></arg><arg name="first6">B.<space/></arg><arg name="last7">Kimpel<space/></arg><arg name="first7">S.<space/></arg><arg name="last8">Koch<space/></arg><arg name="first8">H.<space/></arg><arg name="last9">Mach<space/></arg><arg name="first9">K.<space/></arg><arg name="last10">Hahn<space/></arg><arg name="first10">E. G.<space/></arg><arg name="last11">Konturek<space/></arg><arg name="first11">P. C.<space/></arg><arg name="title">Significance of salicylate intolerance in diseases of the lower gastrointestinal tract<space/></arg><arg name="journal">J. Physiol. Pharmacol.<space/></arg><arg name="volume">56 Suppl 5<space/></arg><arg name="pages">89–102<space/></arg><arg name="year">2005<space/></arg><arg name="pmid">16247191<space/></arg><arg name="url">http://www.jpp.krakow.pl/journal/archive/09_05_s5/pdf/89_09_05_s5_article.pdf<space/></arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref' name="pmid8566739"><template><target>Cite journal</target><arg name="author"><space/>Senna GE, Andri G, Dama AR, Mezzelani P, Andri L<space/></arg><arg name="title"><space/>Tolerability of imidazole salycilate in aspirin-sensitive patients<space/></arg><arg name="journal"><space/>Allergy Proc<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>251–4<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="pmid"><space/>8566739<space/></arg><arg name="doi"><space/>10.2500/108854195778702675<space/></arg></template></extension><space/>or a more generalized<space/><link><target>drug intolerance</target></link><space/>to NSAIDs, and caution should be exercised in those with<space/><link><target>asthma</target></link><space/>or NSAID-precipitated<space/><link><target>bronchospasm</target></link>. Owing to its effect on the stomach lining, manufacturers recommend people with<space/><link><target>peptic ulcer</target><trail>s</trail></link>, mild<space/><link><target>diabetes</target></link>, or<space/><link><target>gastritis</target></link><space/>seek medical advice before using aspirin.<extension extension_name='ref' name="drugs.com"></extension><extension extension_name='ref' name="mercksource"><template><target>cite web</target><arg name="title"><space/>PDR Guide to Over the Counter (OTC) Drugs</arg><arg name="url">http://www.mercksource.com/pp/us/cns/cns_hl_pdr.jspzQzpgzEzzSzppdocszSzuszSzcnszSzcontentzSzpdrotczSzotc_fullzSzdrugszSzfgotc036zPzhtm</arg><arg name="accessdate">28 April 2008</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080410223441/http://www.mercksource.com/pp/us/cns/cns_hl_pdr.jspzQzpgzEzzSzppdocszSzuszSzcnszSzcontentzSzpdrotczSzotc_fullzSzdrugszSzfgotc036zPzhtm</arg><arg name="archivedate"><space/>10 April 2008<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><space/>Even if none of these conditions is present, the risk of<space/><link><target>gastrointestinal hemorrhage</target><part>stomach bleeding</part></link><space/>is still increased when aspirin is taken with<space/><link><target>alcoholic beverage</target><part>alcohol</part></link><space/>or<space/><link><target>warfarin</target></link>.<extension extension_name='ref' name="drugs.com"></extension><extension extension_name='ref' name="personalmd"></extension><space/>Patients with<space/><link><target>hemophilia</target></link><space/>or other bleeding tendencies should not take aspirin or other salicylates.<extension extension_name='ref' name="drugs.com"></extension><extension extension_name='ref' name="mercksource"></extension><space/>Aspirin is known to cause<space/><link><target>hemolytic anemia</target></link><space/>in people who have the genetic disease<space/><link><target>glucose-6-phosphate dehydrogenase deficiency</target></link>, particularly in large doses and depending on the severity of the disease.<extension extension_name='ref'><template><target>Cite book</target><arg name="title"><space/>Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants, and ovalocytosis in human populations</arg><arg name="url">https://books.google.com/?id</arg><arg name="publisher">Oxford University Press</arg><arg name="isbn"><space/>0-19-503634-4</arg><arg name="author"><space/>Livingstone, Frank B.<space/></arg><arg name="year"><space/>1985</arg></template></extension><space/>Use of aspirin during<space/><link><target>dengue fever</target></link><space/>is not recommended owing to increased bleeding tendency.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Dengue and Dengue Hemorrhagic Fever: Information for Health Care Practitioners</arg><arg name="url"><space/>http://www.cdc.gov/NCIDOD/dvbid/dengue/dengue-hcp.htm</arg><arg name="accessdate">28 April 2008</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080317070305/http://www.cdc.gov/Ncidod/dvbid/dengue/dengue-hcp.htm<space/></arg><arg name="archivedate"><space/>17 March 2008</arg></template></extension><space/>People with<space/><link><target>kidney disease</target></link>,<space/><link><target>hyperuricemia</target></link>, or<space/><link><target>gout</target></link><space/>should not take aspirin because it inhibits the kidneys' ability to excrete<space/><link><target>uric acid</target></link>, thus may exacerbate these conditions. Aspirin should not be given to children or adolescents to control cold or influenza symptoms, as this has been linked with Reye's syndrome.<extension extension_name='ref' name="BMJ2002-Macdonald"></extension></preline></preblock><heading level='3'>Gastrointestinal</heading><paragraph>Aspirin use has been shown to increase the risk of gastrointestinal bleeding.<extension extension_name='ref' name="H Toft"><template><target>Cite journal</target><arg name="author">Sørensen HT<space/></arg><arg name="title">Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin<space/></arg><arg name="journal">Am. J. Gastroenterol.<space/></arg><arg name="volume">95<space/></arg><arg name="issue">9<space/></arg><arg name="pages">2218–24<space/></arg><arg name="year">2000<space/></arg><arg name="pmid">11007221<space/></arg><arg name="doi">10.1111/j.1572-0241.2000.02248.x<space/></arg><arg name="author2">Mellemkjaer L</arg><arg name="author3">Blot WJ</arg><arg name="last4">Nielsen</arg><arg name="first4">Gunnar Lauge</arg><arg name="last5">Steffensen</arg><arg name="first5">Flemming Hald</arg><arg name="last6">McLaughlin</arg><arg name="first6">Joseph K.</arg><arg name="last7">Olsen</arg><arg name="first7">Jorgen H.</arg></template></extension><space/>Although some<space/><link><target>Enteric coating</target><part>enteric-coated</part></link><space/>formulations of aspirin are advertised as being &quot;gentle to the stomach&quot;, in one study, enteric coating did not seem to reduce this risk.<extension extension_name='ref' name="H Toft"></extension><space/>Combining aspirin with other<space/><link><target>NSAID</target><trail>s</trail></link><space/>has also been shown to further increase this risk.<extension extension_name='ref' name="H Toft"></extension><space/>Using aspirin in combination with clopidogrel or warfarin also increases the risk of upper gastrointestinal bleeding.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Delaney JA, Opatrny L, Brophy JM & Suissa S<space/></arg><arg name="year">2007<space/></arg><arg name="title">Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding<space/></arg><arg name="journal">CMAJ<space/></arg><arg name="volume">177<space/></arg><arg name="issue">4<space/></arg><arg name="pages">347–51<space/></arg><arg name="pmid">17698822<space/></arg><arg name="doi">10.1503/cmaj.070186<space/></arg><arg name="pmc">1942107</arg></template></extension></paragraph><paragraph>Blockade of COX-1 by aspirin apparently results in the upregulation of COX-2 as part of a gastric defense<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Wallace<space/></arg><arg name="first1"><space/>J. L.<space/></arg><arg name="title"><space/>Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?<space/></arg><arg name="journal"><space/>Physiological Reviews<space/></arg><arg name="volume"><space/>88<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>1547–1565<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18923189<space/></arg><arg name="doi"><space/>10.1152/physrev.00004.2008<space/></arg><arg name="url"><space/>http://physrev.physiology.org/content/88/4/1547.full<space/></arg></template></extension><space/>and that taking COX-2 inhibitors concurrently with aspirin increases the gastric mucosal erosion.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Fiorucci<space/></arg><arg name="first1"><space/>S.<space/></arg><arg name="last2"><space/>Santucci<space/></arg><arg name="first2"><space/>L.<space/></arg><arg name="last3"><space/>Wallace<space/></arg><arg name="first3"><space/>J. L.<space/></arg><arg name="last4"><space/>Sardina<space/></arg><arg name="first4"><space/>M.<space/></arg><arg name="last5"><space/>Romano<space/></arg><arg name="first5"><space/>M.<space/></arg><arg name="last6"><space/>Del Soldato<space/></arg><arg name="first6"><space/>P.<space/></arg><arg name="last7"><space/>Morelli<space/></arg><arg name="first7"><space/>A.<space/></arg><arg name="title"><space/>Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa<space/></arg><arg name="journal"><space/>Proceedings of the National Academy of Sciences<space/></arg><arg name="volume"><space/>100<space/></arg><arg name="issue"><space/>19<space/></arg><arg name="pages"><space/>10937–10941<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12960371<space/></arg><arg name="pmc"><space/>196906<space/></arg><arg name="doi"><space/>10.1073/pnas.1933204100<space/></arg></template></extension><space/>Therefore, caution should be exercised if combining aspirin with any &quot;natural&quot; supplements with COX-2-inhibiting properties, such as garlic extracts, curcumin, bilberry, pine bark, ginkgo, fish oil, resveratrol, genistein, quercetin, resorcinol, and others.</paragraph><paragraph>In addition to enteric coating, &quot;buffering&quot; is the other main method companies have used to try to mitigate the problem of gastrointestinal bleeding. Buffering agents are intended to work by preventing the aspirin from concentrating in the walls of the stomach, although the benefits of buffered aspirin are disputed. Almost any buffering agent used in antacids can be used; Bufferin, for example, uses<space/><link><target>magnesium oxide</target></link>. Other preparations use<space/><link><target>calcium carbonate</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://antoine.frostburg.edu/chem/senese/101/acidbase/faq/buffered-aspirin.shtml<space/></arg><arg name="title">General Chemistry Online: FAQ: Acids and bases: What is the buffer system in buffered aspirin?<space/></arg><arg name="publisher">Antoine.frostburg.edu<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension></paragraph><paragraph>Taking it with vitamin C is a more recently investigated method of protecting the stomach lining. Taking equal doses of vitamin C and aspirin may decrease the amount of stomach damage that occurs compared to taking aspirin alone.<extension extension_name='ref' name="Dammann"><template><target>cite journal</target><arg name="last1"><space/>Dammann<space/></arg><arg name="first1"><space/>H. G.<space/></arg><arg name="last2"><space/>Saleki<space/></arg><arg name="first2"><space/>M.<space/></arg><arg name="last3"><space/>Torz<space/></arg><arg name="first3"><space/>M.<space/></arg><arg name="last4"><space/>Schulz<space/></arg><arg name="first4"><space/>H. U.<space/></arg><arg name="last5"><space/>Krupp<space/></arg><arg name="first5"><space/>S.<space/></arg><arg name="last6"><space/>Schürer<space/></arg><arg name="first6"><space/>M.<space/></arg><arg name="last7"><space/>Timm<space/></arg><arg name="first7"><space/>J.<space/></arg><arg name="last8"><space/>Gessner<space/></arg><arg name="first8"><space/>U.<space/></arg><arg name="title"><space/>Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects<space/></arg><arg name="journal"><space/>Alimentary pharmacology & therapeutics<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>367–374<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>14984384<space/></arg><arg name="doi"><space/>10.1111/j.1365-2036.2004.01742.x<space/></arg></template></extension><extension extension_name='ref' name="Konturek"><template><target>Cite journal</target><arg name="author"><space/>Konturek<space/></arg><arg name="title"><space/>Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase<space/></arg><arg name="journal"><space/>J Physiol Pharmacol.<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>125–36<space/></arg><arg name="pmid"><space/>17218764<space/></arg><arg name="last2"><space/>Kania<space/></arg><arg name="first2"><space/>J<space/></arg><arg name="last3"><space/>Hahn<space/></arg><arg name="first3"><space/>EG<space/></arg><arg name="last4"><space/>Konturek<space/></arg><arg name="first4"><space/>JW<space/></arg><arg name="volume"><space/>57 Suppl 5<space/></arg></template></extension></paragraph><heading level='3'>Central effects</heading><paragraph>Large doses of<space/><link><target>salicylate</target></link>, a metabolite of aspirin, cause temporary<space/><link><target>tinnitus</target></link><space/>(ringing in the ears) based on experiments in rats, via the action on<space/><link><target>arachidonic acid</target></link><space/>and<space/><link><target>NMDA receptor</target><trail>s</trail></link><space/>cascade.<extension extension_name='ref' name="Gutton"><template><target>Cite journal</target><arg name="author">Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL<space/></arg><arg name="title">Salicylate induces tinnitus through activation of cochlear NMDA receptors<space/></arg><arg name="journal">J. Neurosci.<space/></arg><arg name="volume">23<space/></arg><arg name="issue">9<space/></arg><arg name="pages">3944–52<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12736364<space/></arg><arg name="url">http://www.jneurosci.org/cgi/content/full/23/9/3944</arg></template></extension></paragraph><heading level='3'>Reye's syndrome</heading><paragraph><template><target>Main</target><arg>Reye's syndrome</arg></template>Reye's syndrome, a rare but severe illness characterized by acute<space/><link><target>encephalopathy</target></link><space/>and<space/><link><target>fatty liver</target></link>, can occur when children or adolescents are given aspirin for a fever or other illnesses or infections. From 1981 through 1997, 1207 cases of Reye's syndrome in under-18 patients were reported to the U.S.<space/><link><target>Centers for Disease Control and Prevention</target></link>. Of these, 93% reported being ill in the three weeks preceding onset of Reye's syndrome, most commonly with a<space/><link><target>Respiratory tract infection (disambiguation)</target><part>respiratory infection</part></link>,<space/><link><target>chickenpox</target></link>, or<space/><link><target>diarrhea</target></link>. Salicylates were detectable in 81.9% of children for whom test results were reported.<extension extension_name='ref' name="Belay"><template><target>Cite journal</target><arg name="author">Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB<space/></arg><arg name="title">Reye's syndrome in the United States from 1981 through 1997<space/></arg><arg name="journal">N. Engl. J. Med.<space/></arg><arg name="volume">340<space/></arg><arg name="issue">18<space/></arg><arg name="pages">1377–82<space/></arg><arg name="year">1999<space/></arg><arg name="pmid">10228187<space/></arg><arg name="doi"><space/>10.1056/NEJM199905063401801</arg></template></extension><space/>After the association between Reye's syndrome and aspirin was reported, and safety measures to prevent it (including a<space/><link><target>Surgeon General of the United States</target><part>Surgeon General</part></link>'s warning, and changes to the labeling of aspirin-containing drugs) were implemented, aspirin taken by children declined considerably in the United States, as did the number of reported cases of Reye's syndrome; a similar decline was found in the United Kingdom after warnings against pediatric aspirin use were issued.<extension extension_name='ref' name="Belay"></extension><space/>The U.S.<space/><link><target>Food and Drug Administration (United States)</target><part>Food and Drug Administration</part></link><space/>now recommends aspirin (or aspirin-containing products) should not be given to anyone under the age of 12 who has a fever,<extension extension_name='ref' name="BMJ2002-Macdonald"></extension><space/>and the British<space/><link><target>Medicines and Healthcare products Regulatory Agency</target></link><space/>recommends children who are under 16 years of age should not take aspirin, unless it is on the advice of a doctor.<extension extension_name='ref'><link type='external' href='http://www.nhs.uk/conditions/Reyes-syndrome/Pages/Introduction.aspx'>Reye's syndrome</link>. nhs.uk</extension></paragraph><heading level='3'>Hives and swelling</heading><paragraph>For a small number of people, taking aspirin can result in symptoms resembling an allergic reaction, including<space/><link><target>hives</target></link>, swelling, and headache. The reaction is caused by<space/><link><target>salicylate intolerance</target></link><space/>and is not a true<space/><link><target>allergy</target></link>, but rather an inability to metabolize even small amounts of aspirin, resulting in an<space/><link><target>#Overdose</target><part>overdose</part></link>.</paragraph><heading level='3'>Other adverse effects</heading><paragraph>Aspirin can induce<space/><link><target>angioedema</target><part>swelling of skin tissues</part></link><space/>in some people. In one study, angioedema appeared one to six hours after ingesting aspirin in some of the patients. However, when the aspirin was taken alone, it did not cause angioedema in these patients; the aspirin had been taken in combination with another NSAID-induced drug when angioedema appeared.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Berges-Gimeno MP & Stevenson DD<space/></arg><arg name="year">2004<space/></arg><arg name="title">Nonsteroidal anti-inflammatory drug-induced reactions and desensitization<space/></arg><arg name="journal">J Asthma<space/></arg><arg name="volume">41<space/></arg><arg name="issue">4<space/></arg><arg name="pages">375–84<space/></arg><arg name="pmid">15281324<space/></arg><arg name="doi">10.1081/JAS-120037650</arg></template></extension></paragraph><paragraph>Aspirin causes an increased risk of cerebral microbleeds having the appearance on<space/><link><target>MRI</target></link><space/>scans of 5 to 10&amp;nbsp;mm or smaller, hypointense (dark holes) patches.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Vernooij MW, Haag MD, der Lugt A, Hofman A, Krestin GP, Stricker BH, Breteler MM<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="title"><space/>Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study</arg><arg name="journal"><space/>Arch Neurol<space/></arg><arg name="volume"><space/>66<space/></arg><arg name="issue"><space/>6</arg><arg name="pages"><space/>714–20<space/></arg><arg name="pmid"><space/>19364926<space/></arg><arg name="doi">10.1001/archneurol.2009.42</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gorelick PB<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="title"><space/>Cerebral microbleeds: evidence of heightened risk associated with aspirin use<space/></arg><arg name="journal"><space/>Arch Neurol<space/></arg><arg name="volume"><space/>66<space/></arg><arg name="issue"><space/>6</arg><arg name="pages"><space/>691–3<space/></arg><arg name="pmid"><space/>19506128<space/></arg><arg name="doi">10.1001/archneurol.2009.85</arg></template></extension><space/>Such cerebral microbleeds are important, since they often occur prior to<space/><link><target>ischemic stroke</target></link><space/>or<space/><link><target>intracerebral hemorrhage</target></link>,<space/><link><target>Binswanger disease</target></link>, and<space/><link><target>Alzheimer's disease</target></link>.<template><target>Or</target><arg name="date">March 2011</arg></template></paragraph><paragraph>A study of a group with a mean dosage of aspirin of 270&amp;nbsp;mg per day estimated an average absolute risk increase in<space/><link><target>intracerebral hemorrhage</target></link><space/>(ICH) of 12 events per 10,000 persons.<extension extension_name='ref' name="He1998"></extension><space/>In comparison, the estimated absolute risk reduction in myocardial infarction was 137 events per 10,000 persons, and a reduction of 39 events per 10,000 persons in ischemic stroke.<extension extension_name='ref' name="He1998"><template><target>cite journal</target><arg name="last1"><space/>He<space/></arg><arg name="first1"><space/>J.<space/></arg><arg name="last2"><space/>Whelton<space/></arg><arg name="first2"><space/>P. K.<space/></arg><arg name="last3"><space/>Vu<space/></arg><arg name="first3"><space/>B.<space/></arg><arg name="last4"><space/>Klag<space/></arg><arg name="first4"><space/>M. J.<space/></arg><arg name="title"><space/>Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials<space/></arg><arg name="journal"><space/>JAMA: the Journal of the American Medical Association<space/></arg><arg name="volume"><space/>280<space/></arg><arg name="issue"><space/>22<space/></arg><arg name="pages"><space/>1930–1935<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>9851479<space/></arg><arg name="doi"><space/>10.1001/jama.280.22.1930<space/></arg></template></extension><space/>In cases where ICH already has occurred, aspirin use results in higher mortality, with a dose of about 250&amp;nbsp;mg per day resulting in a<space/><link><target>relative risk</target></link><space/>of death within three months after the ICH around 2.5 (95%<space/><link><target>confidence interval</target></link><space/>1.3 to 4.6).<extension extension_name='ref' name="Saloheimo2006"><template><target>cite journal</target><arg name="last1"><space/>Saloheimo<space/></arg><arg name="first1"><space/>P.<space/></arg><arg name="last2"><space/>Ahonen<space/></arg><arg name="first2"><space/>M.<space/></arg><arg name="last3"><space/>Juvela<space/></arg><arg name="first3"><space/>S.<space/></arg><arg name="last4"><space/>Pyhtinen<space/></arg><arg name="first4"><space/>J.<space/></arg><arg name="last5"><space/>Savolainen<space/></arg><arg name="first5"><space/>E. R.<space/></arg><arg name="last6"><space/>Hillbom<space/></arg><arg name="first6"><space/>M.<space/></arg><arg name="title"><space/>Regular Aspirin-Use Preceding the Onset of Primary Intracerebral Hemorrhage is an Independent Predictor for Death<space/></arg><arg name="journal"><space/>Stroke<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>129–133<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16322483<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1161/01.STR.0000196991.03618.31<space/></arg></template></extension></paragraph><paragraph>Aspirin and other NSAIDs can cause<space/><link><target>hyperkalemia</target></link><space/>by inducing a<space/><link><target>hyporeninemic hypoaldosteronism</target><part>hyporeninemic hypoaldosteronic state</part></link><space/>via inhibition of prostaglandin synthesis; however, these agents do not typically cause hyperkalemia by themselves in the setting of normal renal function and euvolemic state.<extension extension_name='ref'>Medical knowledge self-assessment program for students 4, By American College of Physicians, Clerkship Directors in Internal Medicine, Nephrology 227, Item 29</extension></paragraph><paragraph>Aspirin can cause prolonged bleeding after operations for up to 10 days. In one study, 30 of 6499 elective surgical patients required reoperations to control bleeding. Twenty had diffuse bleeding and 10 had bleeding from a site. Diffuse, but not discrete, bleeding was associated with the preoperative use of aspirin alone or in combination with other NSAIDS in 19 of the 20 diffuse bleeding patients.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Scher, K.S.<space/></arg><arg name="year">1996<space/></arg><arg name="title">Unplanned reoperation for bleeding<space/></arg><arg name="journal">Am Surg<space/></arg><arg name="volume">62<space/></arg><arg name="issue">1<space/></arg><arg name="pages">52–55<space/></arg><arg name="pmid">8540646</arg></template></extension></paragraph><paragraph>On 9 July 2015, the<space/><link><target>FDA</target></link><space/>toughened warnings of increased<space/><link><target>heart attack</target></link><space/>and<space/><link><target>stroke</target></link><space/>risk associated with<space/><link><target>nonsteroidal anti-inflammatory drug</target><trail>s</trail></link><space/>(NSAID). Aspirin is an NSAID but is not affected by the new warnings.<extension extension_name='ref' name="FDA-20150709"><template><target>cite web</target><arg name="author">Staff<space/></arg><arg name="title">FDA Strengthens Warning of Heart Attack and Stroke Risk for Non-Steroidal Anti-Inflammatory Drugs<space/></arg><arg name="url">http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm453610.htm<space/></arg><arg name="date">9 July 2015<space/></arg><arg name="work">[[FDA]]<space/></arg><arg name="accessdate">9 July 2015<space/></arg></template></extension></paragraph><paragraph><template><target>Bleeding worksheet</target></template></paragraph><heading level='3'>Overdose</heading><paragraph><template><target>Main</target><arg>Aspirin poisoning</arg></template>Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, higher than normal doses are taken over a period of time. Acute overdose has a<space/><link><target>mortality rate</target></link><space/>of 2%. Chronic overdose is more commonly lethal, with a mortality rate of 25%;<extension extension_name='ref'><template><target>cite web</target><arg name="author">Kreplick, LW.</arg><arg name="year">2001</arg><arg name="title">Salicylate Toxicity in Emergency Medicine</arg><arg name="publisher"><space/>[[Medscape]]</arg><arg name="url">http://misc.medscape.com/pi/android/medscapeapp/html/A818242-business.html</arg></template></extension><space/>chronic overdose may be especially severe in children.<extension extension_name='ref' name="Pediatrics1982-gaudreault"><template><target>Cite journal</target><arg name="author">Gaudreault P, Temple AR, Lovejoy FH Jr<space/></arg><arg name="title">The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison<space/></arg><arg name="journal">Pediatrics<space/></arg><arg name="year">1982<space/></arg><arg name="pages">566–9<space/></arg><arg name="volume">70<space/></arg><arg name="issue">4<space/></arg><arg name="pmid"><space/>7122154</arg></template><space/>(primary source)</extension><space/>Toxicity is managed with a number of potential treatments, including<space/><link><target>activated charcoal</target></link>, intravenous dextrose and normal saline,<space/><link><target>sodium bicarbonate</target></link>, and<space/><link><target>dialysis</target></link>.<extension extension_name='ref'><template><target>Cite book</target><arg name="title">Rosen's emergency medicine: concepts and clinical practice<space/></arg><arg name="last">Marx<space/></arg><arg name="first">John<space/></arg><arg name="year">2006<space/></arg><arg name="publisher">Mosby/Elsevier<space/></arg><arg name="isbn">978-0-323-02845-5<space/></arg><arg name="page">2242</arg></template></extension><space/>The diagnosis of poisoning usually involves measurement of plasma salicylate, the active metabolite of aspirin, by automated spectrophotometric methods. Plasma salicylate levels in general range from 30100&amp;nbsp;mg/l after usual therapeutic doses, 50300&amp;nbsp;mg/l in patients taking high doses and 7001400&amp;nbsp;mg/l following acute overdose. Salicylate is also produced as a result of exposure to<space/><link><target>bismuth subsalicylate</target></link>,<space/><link><target>methyl salicylate</target></link>, and<space/><link><target>sodium salicylate</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA<space/></arg><arg name="title">Serum concentrations of salicylic acid following topically applied salicylate derivatives<space/></arg><arg name="journal">Ann. Pharmacother<space/></arg><arg name="volume">30<space/></arg><arg name="pages">935–40<space/></arg><arg name="year">1996<space/></arg><arg name="pmid">8876850<space/></arg><arg name="issue">9</arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="author">R. Baselt<space/></arg><arg name="title">Disposition of Toxic Drugs and Chemicals in Man<space/></arg><arg name="edition">9th<space/></arg><arg name="publisher">Biomedical Publications<space/></arg><arg name="location">Seal Beach, California<space/></arg><arg name="year">2011<space/></arg><arg name="pages">20–23</arg></template></extension></paragraph><heading level='3'>Interactions</heading><paragraph>Aspirin is known to<space/><link><target>Drug interaction</target><part>interact</part></link><space/>with other drugs. For example,<space/><link><target>acetazolamide</target></link><space/>and<space/><link><target>ammonium chloride</target></link><space/>are known to enhance the intoxicating effect of salicylates, and alcohol, and also increases the gastrointestinal bleeding associated with these types of drugs.<extension extension_name='ref' name='drugs.com'><template><target>cite web</target><arg name="url">http://www.drugs.com/aspirin.html<space/></arg><arg name="title">Aspirin information from Drugs.com<space/></arg><arg name="accessdate">8 May 2008<space/></arg><arg name="publisher">Drugs.com</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080509163105/http://www.drugs.com/aspirin.html</arg><arg name="archivedate"><space/>9 May 2008<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><extension extension_name='ref' name='personalmd'><template><target>cite web</target><arg name="url">http://www.personalmd.com/drgdb/3.htm<space/></arg><arg name="title">Oral Aspirin information<space/></arg><arg name="accessdate">8 May 2008<space/></arg><arg name="publisher">First DataBank</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080609015511/http://www.personalmd.com/drgdb/3.htm</arg><arg name="archivedate"><space/>9 June 2008<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><space/>Aspirin is known to displace a number of drugs from protein-binding sites in the blood, including the<space/><link><target>antidiabetic drug</target><trail>s</trail></link><space/><link><target>tolbutamide</target></link><space/>and<space/><link><target>chlorpropamide</target></link>,<space/><link><target>warfarin</target></link>,<space/><link><target>methotrexate</target></link>,<space/><link><target>phenytoin</target></link>,<space/><link><target>probenecid</target></link>,<space/><link><target>valproic acid</target></link><space/>(as well as interfering with<space/><link><target>beta oxidation</target></link>, an important part of valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Ibuprofen can negate the antiplatelet effect of aspirin used for cardioprotection and stroke prevention.<extension extension_name='ref' name='FDA2006'><template><target>cite web</target><arg name="url"><space/>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222.htm<space/></arg><arg name="title"><space/>Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin<space/></arg><arg name="accessdate">22 November 2010<space/></arg><arg name="date"><space/>September 2006<space/></arg><arg name="work"><space/>FDA<space/></arg><arg name="publisher"><space/>[[U.S. Department of Health & Human Services]]</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20101113035657/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222.htm</arg><arg name="archivedate">13 November 2010<space/></arg><arg name="deadurl">no</arg></template></extension><space/>The pharmacological activity of<space/><link><target>spironolactone</target></link><space/>may be reduced by taking aspirin, and it is known to compete with<space/><link><target>Penicillin</target><part>penicillin G</part></link><space/>for renal tubular secretion.<extension extension_name='ref' name="interactions">Katzung (1998),<space/><italics>Basic and Clinical Pharmacology</italics>, McGraw-Hill, p. 584.</extension><space/>Aspirin may also inhibit the absorption of vitamin C.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Loh HS, Watters K & Wilson CW<space/></arg><arg name="date">1 November 1973</arg><arg name="title">The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings<space/></arg><arg name="journal">J Clin Pharmacol<space/></arg><arg name="volume">13<space/></arg><arg name="issue">11<space/></arg><arg name="pages">480–6<space/></arg><arg name="pmid">4490672<space/></arg><arg name="url">http://jcp.sagepub.com/cgi/content/abstract/13/11/480<space/></arg><arg name="doi">10.1002/j.1552-4604.1973.tb00203.x</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Basu TK<space/></arg><arg name="year">1982<space/></arg><arg name="title">Vitamin C-aspirin interactions<space/></arg><arg name="journal">Int J Vitam Nutr Res Suppl<space/></arg><arg name="volume">23<space/></arg><arg name="pages">83–90<space/></arg><arg name="pmid">6811490</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Ioannides C, Stone AN, Breacker PJ & Basu TK<space/></arg><arg name="year">1982<space/></arg><arg name="title">Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigs<space/></arg><arg name="journal">[[Biochem Pharmacol]]<space/></arg><arg name="volume">31<space/></arg><arg name="issue">24<space/></arg><arg name="pages">4035–8<space/></arg><arg name="pmid">6818974<space/></arg><arg name="doi">10.1016/0006-2952(82)90652-9</arg></template></extension></paragraph><heading level='2'>Chemical properties</heading><paragraph>Aspirin decomposes rapidly in solutions of<space/><link><target>ammonium acetate</target></link><space/>or of the<space/><link><target>acetate</target><trail>s</trail></link>,<space/><link><target>carbonate</target><trail>s</trail></link>,<space/><link><target>citrate</target><trail>s</trail></link>, or<space/><link><target>hydroxide</target><trail>s</trail></link><space/>of the<space/><link><target>alkali metals</target></link>. It is stable in dry air, but gradually<space/><link><target>hydrolyses</target></link><space/>in contact with moisture to acetic and salicylic acids. In solution with alkalis, the hydrolysis proceeds rapidly and the clear solutions formed may consist entirely of acetate and salicylate.<extension extension_name='ref'><template><target>cite encyclopedia</target><arg name="editor">EF Reynolds</arg><arg name="encyclopedia">Martindale: The Extra Pharmacopoeia</arg><arg name="edition">28th</arg><arg name="year">1982</arg><arg name="pages">234–82</arg><arg name="title">Aspirin and similar analgesic and anti-inflammatory agents</arg></template></extension></paragraph><paragraph>Like<space/><link><target>flour mill</target><trail>s</trail></link>, factories that make aspirin tablets must pay attention to how much of the powder gets into the air inside the building, because<space/><link><target>dust explosion</target><part>the powder-air mixture can be explosive</part></link>. The<space/><link><target>National Institute for Occupational Safety and Health</target></link><space/>(NIOSH) has set a<space/><link><target>recommended exposure limit</target></link><space/>in the United States of 5&amp;nbsp;mg/m<xhtml:sup>3</xhtml:sup><space/>(time-weighted average).<extension extension_name='ref'><template><target>Cite web</target><arg name="url"><space/>http://www.cdc.gov/niosh/npg/npgd0010.html</arg><arg name="title"><space/>Acetylsalicylic acid</arg><arg name="date"><space/>February 13, 2015</arg><arg name="accessdate"><space/></arg><arg name="website"><space/>Pocket Guide to Chemical Hazards</arg><arg name="publisher"><space/>NIOSH</arg><arg name="last"><space/></arg><arg name="first"><space/></arg></template></extension><space/>In 1989, OSHA set a legal<space/><link><target>permissible exposure limit</target></link><space/>for aspirin of 5&amp;nbsp;mg/m<xhtml:sup>3</xhtml:sup>, but this was vacated by the<space/><link><target>AFL-CIO v. OSHA</target></link><space/>decision in 1993.<extension extension_name='ref'><template><target>Cite web</target><arg name="url"><space/>http://www.cdc.gov/niosh/npg/nengapdxg.html</arg><arg name="title"><space/>Appendix G: 1989 Air Contaminants Update Project - Exposure Limits NOT in Effect</arg><arg name="date"><space/>February 13, 2015</arg><arg name="accessdate"><space/></arg><arg name="website"><space/>NIOSH Pocket Guide to Chemical Hazards</arg><arg name="publisher"><space/>NIOSH</arg><arg name="last"><space/></arg><arg name="first"><space/></arg></template></extension></paragraph><heading level='2'>Physical properties</heading><paragraph>Aspirin, an<space/><link><target>acetyl</target></link><space/>derivative of salicylic acid, is a white, crystalline, weakly acidic substance, with a<space/><link><target>melting point</target></link><space/>of<space/><template><target>convert</target><arg>136</arg><arg>C</arg><arg>F</arg></template>, and a boiling point of<space/><template><target>convert</target><arg>140</arg><arg>C</arg><arg>F</arg></template>.<extension extension_name='ref' name="Myers2007"><template><target>cite book</target><arg name="author">Richard Leroy Myers</arg><arg name="title">The 100 Most Important Chemical Compounds: A Reference Guide</arg><arg name="url">https://books.google.com/books?id</arg><arg name="accessdate">18 November 2012</arg><arg name="date">30 August 2007</arg><arg name="publisher">ABC-CLIO</arg><arg name="isbn">978-0-313-33758-1</arg><arg name="page">10</arg></template></extension><space/>Its acid dissociation constant (<link><target>Acid dissociation constant</target><part>pK<xhtml:sub>a</xhtml:sub></part></link>) is 3.5 at<space/><template><target>convert</target><arg>25</arg><arg>C</arg><arg>F</arg></template>.<extension extension_name='ref' name="asaaciddissconst"><template><target>cite web</target><arg name="title"><space/>Acetylsalicylic acid</arg><arg name="publisher"><space/>Jinno Laboratory, School of Materials Science, Toyohashi University of Technology</arg><arg name="date"><space/>4 March 1996</arg><arg name="url">http://chrom.tutms.tut.ac.jp/JINNO/DRUGDATA/07acetylsalicylic_acid.html</arg><arg name="archiveurl">https://web.archive.org/web/20120120224558/http://chrom.tutms.tut.ac.jp/JINNO/DRUGDATA/07acetylsalicylic_acid.html</arg><arg name="archivedate">20 January 2012</arg><arg name="accessdate">12 April 2014</arg></template></extension></paragraph><heading level='3'>Synthesis</heading><paragraph>The synthesis of aspirin is classified as an<space/><link><target>ester</target><trail>ification</trail></link><space/>reaction.<space/><link><target>Salicylic acid</target></link><space/>is treated with<space/><link><target>acetic anhydride</target></link>, an acid derivative, causing a chemical reaction that turns salicylic acid's<space/><link><target>hydroxyl</target></link><space/>group into an<space/><link><target>ester</target></link><space/>group (R-OH R-OCOCH<xhtml:sub>3</xhtml:sub>). This process yields aspirin and<space/><link><target>acetic acid</target></link>, which is considered a<space/><link><target>byproduct</target></link><space/>of this reaction. Small amounts of<space/><link><target>sulfuric acid</target></link><space/>(and occasionally<space/><link><target>phosphoric acid</target></link>) are almost always used as a<space/><link><target>catalyst</target></link>. This method is commonly employed in undergraduate teaching labs.<extension extension_name='ref'><template><target>Cite book</target><arg name="title">Experimental Organic Chemistry<space/></arg><arg name="last">Palleros<space/></arg><arg name="first">Daniel R.<space/></arg><arg name="year">2000<space/></arg><arg name="publisher">John Wiley & Sons</arg><arg name="location">New York</arg><arg name="isbn">0-471-28250-2<space/></arg><arg name="page">494</arg></template></extension></paragraph><list type='ident'><listitem><link><target>File:Aspirin synthesis.png</target><part>490px</part></link></listitem></list><list type='def'><listitem><defkey>Reaction mechanism</defkey></listitem></list><list type='ident'><listitem><link><target>File:Acetylation of salicylic acid, mechanism.png</target><part>Acetylation of salicylic acid, mechanism</part><part>800px</part></link></listitem></list><paragraph>Formulations containing high concentrations of aspirin often smell like<space/><link><target>vinegar</target></link><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.newton.dep.anl.gov/askasci/chem00/chem00314.htm<space/></arg><arg name="title">Aspirin Aging<space/></arg><arg name="accessdate">8 May 2008<space/></arg><arg name="last">Barrans<space/></arg><arg name="first">Richard</arg><arg name="publisher">Newton BBS</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080518213137/http://www.newton.dep.anl.gov/askasci/chem00/chem00314.htm</arg><arg name="archivedate"><space/>18 May 2008<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><space/>because aspirin can decompose through hydrolysis in moist conditions, yielding salicylic and acetic acids.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Carstensen<space/></arg><arg name="first1"><space/>J.T.<space/></arg><arg name="author2"><space/>F Attarchi and XP Hou<space/></arg><arg name="title"><space/>Decomposition of aspirin in the solid state in the presence of limited amounts of moisture<space/></arg><arg name="journal"><space/>Journal of Pharmaceutical Sciences<space/></arg><arg name="volume"><space/>77<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>318–21<space/></arg><arg name="year"><space/>1985<space/></arg><arg name="pmid"><space/>4032246<space/></arg><arg name="doi"><space/>10.1002/jps.2600770407<space/></arg></template></extension></paragraph><heading level='3'>Polymorphism</heading><paragraph><link><target>Polymorphism (materials science)</target><part>Polymorphism</part></link>, or the ability of a substance to form more than one<space/><link><target>crystal structure</target></link>, is important in the development of pharmaceutical ingredients. Many drugs are receiving regulatory approval for only a single crystal form or polymorph. For a long time, only one crystal structure for aspirin was known. That aspirin might have a second crystalline form was suspected since the 1960s. The elusive second polymorph was first discovered by Vishweshwar and coworkers in 2005,<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Vishweshwar<space/></arg><arg name="first1"><space/>P.<space/></arg><arg name="last2"><space/>McMahon<space/></arg><arg name="first2"><space/>J. A.<space/></arg><arg name="last3"><space/>Oliveira<space/></arg><arg name="first3"><space/>M.<space/></arg><arg name="last4"><space/>Peterson<space/></arg><arg name="first4"><space/>M. L.<space/></arg><arg name="last5"><space/>Zaworotko<space/></arg><arg name="first5"><space/>M. J.<space/></arg><arg name="title"><space/>The Predictably Elusive Form II of Aspirin<space/></arg><arg name="journal"><space/>Journal of the American Chemical Society<space/></arg><arg name="volume"><space/>127<space/></arg><arg name="issue"><space/>48<space/></arg><arg name="pages"><space/>16802–16803<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16316223<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1021/ja056455b<space/></arg></template></extension><space/>and fine structural details were given by Bond<space/><italics>et al.</italics><extension extension_name='ref'><template><target>Cite journal</target><arg name="author"><space/>Bond, Andrew D.; Boese, Roland; and Desiraju, Gautam R.<space/></arg><arg name="title"><space/>On the Polymorphism of Aspirin: Crystalline Aspirin as Intergrowths of Two "Polymorphic" Domains</arg><arg name="journal"><space/>[[Angewandte Chemie International Edition]]</arg><arg name="year"><space/>2007</arg><arg name="volume"><space/>46</arg><arg name="issue"><space/>4</arg><arg name="pages"><space/>618–622</arg><arg name="doi"><space/>10.1002/anie.200603373</arg><arg name="pmid"><space/>17139692</arg></template></extension><space/>A new crystal type was found after attempted cocrystallization of aspirin and<space/><link><target>levetiracetam</target></link><space/>from hot<space/><link><target>acetonitrile</target></link>. The form II is only stable at 100<template><target>Spaces</target></template><link><target>Kelvin</target><part>K</part></link><space/>and reverts to form I at ambient temperature. In the (unambiguous) form I, two salicylic molecules form centrosymmetric<space/><link><target>Dimer (chemistry)</target><part>dimers</part></link><space/>through the acetyl groups with the (acidic)<space/><link><target>methyl</target></link><space/>proton to<space/><link><target>carbonyl</target></link><space/><link><target>hydrogen bond</target><trail>s</trail></link>, and in the newly claimed form II, each salicylic molecule forms the same hydrogen bonds with two neighboring molecules instead of one. With respect to the hydrogen bonds formed by the<space/><link><target>carboxylic acid</target></link><space/>groups, both polymorphs form identical dimer structures.<template><target>citation needed</target><arg name="date">September 2015</arg></template></paragraph><heading level='2'>Mechanism of action</heading><paragraph><template><target>Main</target><arg>Mechanism of action of aspirin</arg></template></paragraph><preblock><preline></preline></preblock><heading level='3'>Discovery of the mechanism</heading><paragraph>In 1971, British<space/><link><target>pharmacologist</target></link><space/><link><target>John Robert Vane</target></link>, then employed by the<space/><link><target>Royal College of Surgeons of England</target><part>Royal College of Surgeons</part></link><space/>in London, showed aspirin suppressed the production of<space/><link><target>prostaglandin</target><trail>s</trail></link><space/>and<space/><link><target>thromboxane</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>Cite journal</target><arg name="title"><space/>Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs</arg><arg name="author"><space/>Vane, John Robert<space/></arg><arg name="journal"><space/>Nature – New Biology</arg><arg name="year"><space/>1971</arg><arg name="volume"><space/>231</arg><arg name="issue"><space/>25</arg><arg name="pages"><space/>232–5</arg><arg name="pmid"><space/>5284360</arg><arg name="doi"><space/>10.1038/newbio231232a0</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Vane JR, Botting RM<space/></arg><arg name="year">2003<space/></arg><arg name="title">The mechanism of action of aspirin<space/></arg><arg name="journal">Thromb Res<space/></arg><arg name="volume">110<space/></arg><arg name="issue">5–6<space/></arg><arg name="pages">255–8<space/></arg><arg name="pmid">14592543<space/></arg><arg name="doi">10.1016/S0049-3848(03)00379-7<space/></arg><arg name="url">http://www.eao.chups.jussieu.fr/polys/certifopt/saule_coxib/theme/1vane2003.pdf<space/></arg><arg name="format">PDF</arg><arg name="last2">Botting<space/></arg></template></extension><space/>For this discovery he was awarded the 1982<space/><link><target>Nobel Prize in Physiology or Medicine</target></link>, jointly with<space/><link><target>Sune K. Bergstrm</target></link><space/>and<space/><link><target>Bengt I. Samuelsson</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nobelprize.org/nobel_prizes/medicine/laureates/1982/<space/></arg><arg name="title">The Nobel Prize in Physiology or Medicine 1982<space/></arg><arg name="publisher">Nobelprize.or</arg></template></extension><space/>In 1984, he was made a<space/><link><target>Knight Bachelor</target></link>.</paragraph><heading level='3'>Suppression of prostaglandins and thromboxanes</heading><paragraph>Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the<space/><link><target>cyclooxygenase</target></link><space/>(COX; officially known as prostaglandin-endoperoxide synthase, PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a<space/><link><target>serine</target></link><space/>residue in the active site of the PTGS enzyme. This makes aspirin different from other NSAIDs (such as<space/><link><target>diclofenac</target></link><space/>and<space/><link><target>ibuprofen</target></link>), which are reversible inhibitors.</paragraph><paragraph>Low-dose aspirin use irreversibly blocks the formation of<space/><link><target>thromboxane A2</target><part>thromboxane A<xhtml:sub>2</xhtml:sub></part></link><space/>in platelets, producing an inhibitory effect on platelet aggregation during the lifetime of the affected platelet (89 days). This antithrombotic property makes aspirin useful for reducing the incidence of heart attacks.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.americanheart.org/presenter.jhtml?identifier</arg><arg name="title">Aspirin in Heart Attack and Stroke Prevention<space/></arg><arg name="accessdate">8 May 2008<space/></arg><arg name="publisher">American Heart Association<space/></arg><arg name="archiveurl">https://web.archive.org/web/20080331031146/http://www.americanheart.org/presenter.jhtml?identifier</arg><arg name="archivedate">31 March 2008</arg></template></extension><space/>40&amp;nbsp;mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A<xhtml:sub>2</xhtml:sub><space/>release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1">Tohgi<space/></arg><arg name="first1">H<space/></arg><arg name="author2">S Konno, K Tamura, B Kimura and K Kawano</arg><arg name="year"><space/>1992</arg><arg name="title"><space/>Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin</arg><arg name="journal"><space/>Stroke</arg><arg name="volume"><space/>23</arg><arg name="pages"><space/>1400–1403<space/></arg><arg name="pmid">1412574</arg><arg name="issue"><space/>10</arg><arg name="doi">10.1161/01.STR.23.10.1400</arg></template></extension></paragraph><paragraph>Prostaglandins, local<space/><link><target>hormone</target><trail>s</trail></link><space/>produced in the body, have diverse effects, including the transmission of pain information to the brain, modulation of the<space/><link><target>hypothalamus</target><part>hypothalamic</part></link><space/>thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form<space/><link><target>clot</target><part>blood clots</part></link>. Heart attacks are caused primarily by blood clots, and low doses of aspirin are seen as an effective medical intervention for acute myocardial infarction.</paragraph><heading level='3'>COX-1 and COX-2 inhibition</heading><paragraph>At least two different types of cyclooxygenase occur: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. Aspirin-modified PTGS2 produces lipoxins, most of which are anti-inflammatory.<extension extension_name='ref'><template><target>cite journal</target><arg name="volume">2</arg><arg name="issue">3</arg><arg name="title">Pharmacokinetic Solubility And Dissolution Profile of Non-Steroidal Anti-Inflammatory Drugs</arg><arg name="author">Achhrish goel, Ruchi gupta Anubhav goswami Madhu soodan sharma Yogesh sharma</arg><arg name="year">2011</arg></template></extension><space/>Newer NSAID drugs,<space/><link><target>COX-2 inhibitor</target><trail>s</trail></link><space/>(coxibs), have been developed to inhibit only PTGS2, with the intent to reduce the incidence of gastrointestinal side effects.<extension extension_name='ref' name="cox3article"></extension></paragraph><paragraph>However, several of the new COX-2 inhibitors, such as<space/><link><target>rofecoxib</target></link><space/>(Vioxx), have been withdrawn in the last decade, after evidence emerged that PTGS2 inhibitors increase the risk of heart attack and stroke.<extension extension_name='ref'><template><target>cite journal</target><arg name="journal">Curr Pharm Des<space/></arg><arg name="year">2007<space/></arg><arg name="volume">13<space/></arg><arg name="issue">22<space/></arg><arg name="pages">2215–27<space/></arg><arg name="title">Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks<space/></arg><arg name="author">Martínez-González J, Badimon L<space/></arg><arg name="pmid">17691994<space/></arg><arg name="doi">10.2174/138161207781368774</arg><arg name="last2">Badimon<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="journal">J Cardiovasc Pharmacol<space/></arg><arg name="title">COX-2 inhibitors and cardiovascular risk<space/></arg><arg name="author">Funk CD, FitzGerald GA<space/></arg><arg name="date">November 2007<space/></arg><arg name="volume">50<space/></arg><arg name="issue">5<space/></arg><arg name="pages">470–9<space/></arg><arg name="pmid">18030055<space/></arg><arg name="doi">10.1097/FJC.0b013e318157f72d</arg><arg name="last2">Fitzgerald<space/></arg></template></extension><space/>Endothelial cells lining the microvasculature in the body are proposed to express PTGS2, and, by selectively inhibiting PTGS2, prostaglandin production (specifically, PGI2; prostacyclin) is downregulated with respect to thromboxane levels, as PTGS1 in platelets is unaffected. Thus, the protective anticoagulative effect of<space/><link><target>PGI2</target></link><space/>is removed, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new PTGS once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.</paragraph><heading level='3'>Additional mechanisms</heading><paragraph>Aspirin has been shown to have at least three additional modes of action. It uncouples<space/><link><target>oxidative phosphorylation</target></link><space/>in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons.<extension extension_name='ref' name="SomasundaramS"><template><target>Cite journal</target><arg name="author1">Somasundaram</arg><arg name="first2">G</arg><arg name="first3">RJ</arg><arg name="first4">J</arg><arg name="first5">M</arg><arg name="first6">IA</arg><arg name="first7">S</arg><arg name="first8">A</arg><arg name="first9">R</arg><arg name="issue">5</arg><arg name="last2">Sigthorsson</arg><arg name="last3">Simpson</arg><arg name="last4">Watts</arg><arg name="last5">Jacob</arg><arg name="last6">Tavares</arg><arg name="last7">Rafi</arg><arg name="last8">Roseth</arg><arg name="last9">Foster<space/></arg><arg name="year">2000</arg><arg name="title">Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat</arg><arg name="journal">Aliment Pharmacol Ther</arg><arg name="volume">14</arg><arg name="pages">639–650</arg><arg name="doi">10.1046/j.1365-2036.2000.00723.x</arg><arg name="pmid">10792129</arg><arg name="last10">Price</arg><arg name="last11">Wrigglesworth</arg><arg name="last12">Bjarnason</arg><arg name="first10">AB</arg><arg name="first12">I</arg><arg name="displayauthors">9<space/></arg></template></extension><space/>In short, aspirin buffers and transports the protons. When high doses of aspirin are given, it may actually cause fever, owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. In addition, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion, which is an important step in immune response to infection; however, evidence is insufficient to show aspirin helps to fight infection.<extension extension_name='ref'><template><target>Cite journal</target><arg name="first">Mark J.<space/></arg><arg name="last">Paul-Clark<space/></arg><arg name="first2">Thong van<space/></arg><arg name="last2">Cao<space/></arg><arg name="first3">Niloufar<space/></arg><arg name="last3">Moradi-Bidhendi<space/></arg><arg name="first4">Dianne<space/></arg><arg name="last4">Cooper<space/></arg><arg name="first5">Derek W.<space/></arg><arg name="last5">Gilroy<space/></arg><arg name="lastauthoramp">yes<space/></arg><arg name="title">15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation<space/></arg><arg name="journal">J. Exp. Med.<space/></arg><arg name="year">2004<space/></arg><arg name="volume">200<space/></arg><arg name="issue">1<space/></arg><arg name="pages">69–78<space/></arg><arg name="doi">10.1084/jem.20040566<space/></arg><arg name="pmid">15238606<space/></arg><arg name="pmc">2213311</arg></template></extension><space/>More recent data also suggest salicylic acid and its derivatives modulate signaling through<space/><link><target>NF-B</target></link>.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last">McCarty<space/></arg><arg name="first">M. F.<space/></arg><arg name="first2">K. I.<space/></arg><arg name="last2">Block<space/></arg><arg name="year">2006<space/></arg><arg name="title">Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy<space/></arg><arg name="journal">Integr Cancer Ther.<space/></arg><arg name="volume">5<space/></arg><arg name="issue">3<space/></arg><arg name="pages">252–268<space/></arg><arg name="pmid">16880431<space/></arg><arg name="doi">10.1177/1534735406291499</arg></template></extension><space/>NF-B, a<space/><link><target>transcription factor</target></link><space/>complex, plays a central role in many biological processes, including inflammation.</paragraph><paragraph>Aspirin is readily broken down in the body to salicylic acid, which itself has anti-inflammatory, antipyretic, and analgesic effects. In 2012, salicylic acid was found to activate<space/><link><target>AMP-activated protein kinase</target></link>, which has been suggested as a possible explanation for some of the effects of both salicylic acid and aspirin.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Hawley<space/></arg><arg name="first1"><space/>S. A.<space/></arg><arg name="last2"><space/>Fullerton<space/></arg><arg name="first2"><space/>M. D.<space/></arg><arg name="last3"><space/>Ross<space/></arg><arg name="first3"><space/>F. A.<space/></arg><arg name="last4"><space/>Schertzer<space/></arg><arg name="first4"><space/>J. D.<space/></arg><arg name="last5"><space/>Chevtzoff<space/></arg><arg name="first5"><space/>C.<space/></arg><arg name="last6"><space/>Walker<space/></arg><arg name="first6"><space/>K. J.<space/></arg><arg name="last7"><space/>Peggie<space/></arg><arg name="first7"><space/>M. W.<space/></arg><arg name="last8"><space/>Zibrova<space/></arg><arg name="first8"><space/>D.<space/></arg><arg name="last9"><space/>Green<space/></arg><arg name="first9"><space/>K. A.<space/></arg><arg name="last10"><space/>Mustard<space/></arg><arg name="first10"><space/>K. J.<space/></arg><arg name="last11"><space/>Kemp<space/></arg><arg name="first11"><space/>B. E.<space/></arg><arg name="last12"><space/>Sakamoto<space/></arg><arg name="first12"><space/>K.<space/></arg><arg name="last13"><space/>Steinberg<space/></arg><arg name="first13"><space/>G. R.<space/></arg><arg name="last14"><space/>Hardie<space/></arg><arg name="first14"><space/>D. G.<space/></arg><arg name="title"><space/>The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>336<space/></arg><arg name="issue"><space/>6083<space/></arg><arg name="pages"><space/>918–922<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22517326<space/></arg><arg name="pmc"><space/>3399766<space/></arg><arg name="doi"><space/>10.1126/science.1215327<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Raffensperger, Lisa<space/></arg><arg name="url">http://www.newscientist.com/article/dn21718-clues-to-aspirins-anticancer-effects-revealed.html<space/></arg><arg name="title">Clues to aspirin's anti-cancer effects revealed</arg><arg name="journal">New Scientist</arg><arg name="date">19 April 2012</arg><arg name="doi">10.1016/S0262-4079(12)61073-2</arg><arg name="volume">214</arg><arg name="issue">2862</arg><arg name="page">16</arg></template></extension><space/>The acetyl portion of the aspirin molecule has its own targets. Acetylation of cellular proteins is a well-established phenomenon in the regulation of protein function at the post-translational level. Aspirin is able to acetylate several other targets in addition to COX isoenzymes.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Bhat<space/></arg><arg name="title"><space/>Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells<space/></arg><arg name="journal"><space/>International Journal of Oncology<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.3892/ijo_00000185<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Bhat<space/></arg><arg name="title"><space/>Does aspirin acetylate multiple cellular proteins? (Review)<space/></arg><arg name="journal"><space/>Molecular Medicine Reports<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.3892/mmr_00000132<space/></arg></template></extension><space/>These acetylation reactions may explain many hitherto unexplained effects of aspirin.</paragraph><heading level='2'>Pharmacokinetics</heading><paragraph>Acetylsalicylic acid is a<space/><link><target>weak acid</target></link>, and very little of it is<space/><link><target>Acid dissociation constant</target><part>ionized</part></link><space/>in the<space/><link><target>stomach</target></link><space/>after oral administration. Acetylsalicylic acid is quickly absorbed through cell membrane in the<space/><link><target>acidic</target></link><space/>conditions of the stomach. The increased<space/><link><target>pH</target></link><space/>and larger surface area of the<space/><link><target>small intestine</target></link><space/>causes aspirin to be absorbed more slowly there, as more of it is ionised. Owing to the formation of concretions, aspirin is absorbed much more slowly during overdose, and<space/><link><target>blood plasma</target><part>plasma</part></link><space/>concentrations can continue to rise for up to 24 hours after ingestion.<extension extension_name='ref' name="'RK Ferguson'"><template><target>Cite journal</target><arg name="title">Death following self-poisoning with aspirin</arg><arg name="journal">Journal of the American Medical Association</arg><arg name="date">17 August 1970</arg><arg name="first1">RK</arg><arg name="last1">Ferguson</arg><arg name="author2">Boutros, AR</arg><arg name="volume">213</arg><arg name="issue">7</arg><arg name="pages">1186–8</arg><arg name="pmid">5468267</arg><arg name="doi">10.1001/jama.213.7.1186</arg></template></extension><extension extension_name='ref' name="'FL Kaufman'"><template><target>Cite journal</target><arg name="title">Darvon poisoning with delayed salicylism: a case report</arg><arg name="journal">Pediatrics</arg><arg name="date">April 1970</arg><arg name="first1">FL</arg><arg name="last1">Kaufman</arg><arg name="author2">Dubansky, AS</arg><arg name="volume">49</arg><arg name="issue">4</arg><arg name="pages">610–1</arg><arg name="pmid">5013423</arg></template></extension><extension extension_name='ref' name="G Levy"><template><target>Cite journal</target><arg name="doi">10.1056/NEJM197208312870903</arg><arg name="title">Salicylate accumulation kinetics in man<space/></arg><arg name="journal">New England Journal of Medicine<space/></arg><arg name="date">31 August 1972<space/></arg><arg name="first1">G<space/></arg><arg name="last1">Levy<space/></arg><arg name="author2">Tsuchiya, T<space/></arg><arg name="volume">287<space/></arg><arg name="issue">9<space/></arg><arg name="pages">430–2<space/></arg><arg name="pmid">5044917</arg></template></extension></paragraph><paragraph>About 5080% of salicylate in the blood is bound to<space/><link><target>albumin</target><part>albumin protein</part></link>, while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.10.2 l/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.<extension extension_name='ref' name="G Levy"></extension></paragraph><paragraph>As much as 80% of therapeutic doses of salicylic acid is<space/><link><target>metabolism</target><part>metabolized</part></link><space/>in the<space/><link><target>liver</target></link>. Conjugation with<space/><link><target>glycine</target></link><space/>forms<space/><link><target>salicyluric acid</target></link>, and with<space/><link><target>glucuronic acid</target></link><space/>to form two different gluconuride esters. The conjugate with the acetyl group intact is referred to as the<space/><italics>acyl gluconuride</italics>; the deacetylated conjugate is the<space/><italics>phenolic gluconuride</italics>. These metabolic pathways have only a limited capacity. Small amounts of salicylic acid are also hydroxylated to<space/><link><target>gentisic acid</target></link>. With large salicylate doses, the kinetics switch from first-order to zero-order, as<space/><link><target>metabolic pathway</target><trail>s</trail></link><space/>become saturated and<space/><link><target>kidney</target><part>renal</part></link><space/>excretion becomes increasingly important.<extension extension_name='ref' name="G Levy"></extension></paragraph><paragraph>Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid (10%), salicylic phenol (10%), and acyl glucuronides (5%),<space/><link><target>gentisic acid</target></link><space/>(&lt; 1%), and<space/><link><target>2,3-Dihydroxybenzoic acid</target><part>2,3-dihydroxybenzoic acid</part></link>.<extension extension_name='ref'>2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Martin Grootveld and Barry Halliwell, Biochemical Pharmacology, Volume 37, Issue 2, 15 January 1988, pages 271280,<space/><template><target>doi</target><arg>10.1016/0006-2952(88)90729-0</arg></template></extension><space/>When small doses (less than 250&amp;nbsp;mg in an adult) are ingested, all pathways proceed by first-order kinetics, with an elimination half-life of about 2.0 to 4.5 hours.<extension extension_name='ref' name="'O Hartwig'"><template><target>Cite journal</target><arg name="title">Pharmacokinetic considerations of common analgesics and antipyretics</arg><arg name="journal">American Journal of Medicine</arg><arg name="date">14 November 1983</arg><arg name="first">Otto H</arg><arg name="last">Hartwig</arg><arg name="volume">75</arg><arg name="issue">5A</arg><arg name="pages">30–7</arg><arg name="pmid">6606362</arg><arg name="doi">10.1016/0002-9343(83)90230-9</arg></template></extension><extension extension_name='ref' name="'AK Done'"><template><target>Cite journal</target><arg name="title">Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion</arg><arg name="journal">Pediatrics</arg><arg name="date">November 1960</arg><arg name="first">AK</arg><arg name="last">Done</arg><arg name="volume">26</arg><arg name="pages">800–7</arg><arg name="pmid">13723722</arg></template></extension><space/>When higher doses of salicylate are ingested (more than 4 g), the half-life becomes much longer (1530 hours),<extension extension_name='ref' name="Chyka2007"><template><target>Cite journal</target><arg name="author">Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, Caravati EM, Nelson LS, Olson KR, Cobaugh DJ, Scharman EJ, Woolf AD, Troutman WG; Americal Association of Poison Control Centers; Healthcare Systems Bureau, Health Resources and Services Administration, Department of Health and Human Services.<space/></arg><arg name="title">Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management<space/></arg><arg name="journal">Clin Toxicol (Phila)<space/></arg><arg name="volume">45<space/></arg><arg name="issue">2<space/></arg><arg name="pages">95–131<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17364628<space/></arg><arg name="doi">10.1080/15563650600907140</arg></template></extension><space/>because the biotransformation pathways concerned with the formation of salicyluric acid and salicyl phenolic glucuronide become saturated.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author">Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT<space/></arg><arg name="title">Diuresis or urinary alkalinisation for salicylate poisoning?<space/></arg><arg name="journal">Br Med J (Clin Res Ed)<space/></arg><arg name="volume">285<space/></arg><arg name="issue">6352<space/></arg><arg name="pages">1383–6<space/></arg><arg name="year">1982<space/></arg><arg name="pmid">6291695<space/></arg><arg name="pmc">1500395<space/></arg><arg name="doi">10.1136/bmj.285.6352.1383</arg><arg name="last2">Balali-Mood<space/></arg><arg name="last3">Critchley<space/></arg><arg name="last4">Johnstone<space/></arg><arg name="last5">Proudfoot<space/></arg></template></extension><space/>Renal excretion of salicylic acid becomes increasingly important as the metabolic pathways become saturated, because it is extremely sensitive to changes in<space/><link><target>urine</target><part>urinary</part></link><space/>pH. A 10- to 20-fold increase in renal clearance occurs when urine pH is increased from 5 to 8. The use of urinary alkalinization exploits this particular aspect of salicylate elimination.<extension extension_name='ref' name="EmergMed2002-Dargan"><template><target>Cite journal</target><arg name="author">Dargan PI, Wallace CI, Jones AL.</arg><arg name="title">An evidenced based flowchart to guide the management of acute salicylate (aspirin) overdose</arg><arg name="journal">Emerg Med J</arg><arg name="year">2002</arg><arg name="pages">206–9</arg><arg name="volume">19</arg><arg name="issue">3</arg><arg name="pmid"><space/>11971828<space/></arg><arg name="doi">10.1136/emj.19.3.206</arg><arg name="pmc">1725844</arg><arg name="last2">Wallace</arg><arg name="last3">Jones</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph><template><target>Main</target><arg>History of aspirin</arg></template><link><target>File:Aspirine-1923.jpg</target><part>thumb</part><part>left</part><part>1923 advertisement</part></link>Plant extracts, including<space/><link><target>willow</target></link><space/><link><target>bark</target></link><space/>and<space/><link><target>spiraea</target></link>, of which salicylic acid was the<space/><link><target>active ingredient</target><part>active constituent</part></link>, had been known to help alleviate headaches, pains, and fevers since antiquity. The father of modern medicine,<space/><link><target>Hippocrates</target></link><space/>(<italics>circa</italics><space/>460 377 BC), left historical records describing the use of powder made from the bark and leaves of the willow tree to help these symptoms.<extension extension_name='ref'><template><target>cite web</target><arg name="author">Mary Bellis<space/></arg><arg name="url">http://inventors.about.com/library/inventors/blaspirin.htm<space/></arg><arg name="title">History of aspirin<space/></arg><arg name="publisher">Inventors.about.com<space/></arg><arg name="date">16 June 2010<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension></paragraph><paragraph>In 1763, Edward Stone, at Oxford, isolated the active ingredient of aspirin in his discovery of salicylic acid. A French chemist,<space/><link><target>Charles Frederic Gerhardt</target></link>, was the first to prepare acetylsalicylic acid in 1853. In the course of his work on the synthesis and properties of various<space/><link><target>acid anhydride</target><trail>s</trail></link>, he mixed<space/><link><target>acetyl chloride</target></link><space/>with a<space/><link><target>sodium</target></link><space/>salt of salicylic acid (<link><target>sodium salicylate</target></link>). A vigorous reaction ensued, and the resulting melt soon solidified.<extension extension_name='ref' name="gerhardt"><template><target>Cite journal</target><arg name="author">Gerhardt, Ch.</arg><arg name="title">Untersuchungen über die wasserfreien organischen Säuren<space/></arg><arg name="trans_title">Investigations into anhydrous organic acids</arg><arg name="journal">Annalen der Chemie und Pharmacie</arg><arg name="volume">87</arg><arg name="pages">149–179</arg><arg name="year">1853<space/></arg><arg name="url">https://books.google.com/books?id</arg><arg name="doi">10.1002/jlac.18530870107</arg><arg name="language">de</arg></template><space/>See especially pages 162-163.</extension><space/>Since no<space/><link><target>structural theory</target></link><space/>existed at that time, Gerhardt called the compound he obtained &quot;salicylic-acetic anhydride&quot; (<italics>wasserfreie Salicylsure-Essigsure</italics>). This preparation of aspirin (&quot;salicylic-acetic anhydride&quot;) was one of the many reactions Gerhardt conducted for his paper on anhydrides and he did not pursue it further.</paragraph><paragraph><link><target>File:BayerHeroin.png</target><part>thumb</part><part>right</part><part>180px</part><part>Advertisement for Aspirin,<space/><link><target>Heroin</target></link>,<space/><link><target>Lycetol</target></link>, and<space/><link><target>Salophen</target></link></part></link>Six years later, in 1859, von Gilm obtained analytically pure acetylsalicylic acid (which he called<space/><italics>acetylierte Salicylsure</italics>, acetylated salicylic acid) by a reaction of salicylic acid and acetyl chloride.<extension extension_name='ref' name="gilm"><template><target>Cite journal</target><arg name="author">von Gilm H</arg><arg name="title">Acetylderivate der Phloretin- und Salicylsäure</arg><arg name="trans_title">Acetyl derivatives of phloretic and salicylic acids</arg><arg name="journal">Annalen der Chemie und Pharmacie</arg><arg name="volume">112</arg><arg name="issue">2</arg><arg name="pages">180–182</arg><arg name="year">1859</arg><arg name="url">https://books.google.com/books?id</arg><arg name="doi">10.1002/jlac.18591120207</arg><arg name="language">de</arg></template></extension><space/>In 1869, Schrder, Prinzhorn, and Kraut repeated both Gerhardt's (from sodium salicylate) and von Gilm's (from salicylic acid) syntheses and concluded both reactions gave the same compoundacetylsalicylic acid. They were first to assign to it the correct structure with the acetyl group connected to the phenolic oxygen.<extension extension_name='ref'><template><target>Cite journal</target><arg name="author"><space/>Schröder, Prinzhorn, Kraut K</arg><arg name="title">Ueber Salicylverbindungen</arg><arg name="trans_title">On compounds of salicylic acid</arg><arg name="journal">Annalen der Chemie und Pharmacie</arg><arg name="volume">150<space/></arg><arg name="issue">1<space/></arg><arg name="pages">1–20<space/></arg><arg name="year">1869</arg><arg name="url">http://babel.hathitrust.org/cgi/pt?id</arg><arg name="doi">10.1002/jlac.18691500102</arg><arg name="last2">Prinzhorn</arg><arg name="last3">Kraut</arg><arg name="language">de</arg></template>See especially pages 9-13; the structural formula of acetylsalicylic acid appears on p. 12.</extension></paragraph><paragraph>In 1897, chemists working at Bayer AG produced a synthetically altered version of<space/><link><target>salicin</target></link>, derived from the species<space/><italics><link><target>Filipendula ulmaria</target></link></italics><space/>(meadowsweet), which caused less digestive upset than pure salicylic acid. The identity of the lead chemist on this project is a matter of controversy. Bayer states the work was done by<space/><link><target>Felix Hoffmann</target></link>, but the Jewish chemist<space/><link><target>Arthur Eichengrn</target></link><space/>later claimed he was the lead investigator and records of his contribution were expunged under the<space/><link><target>Nazi</target></link><space/>regime.<extension extension_name='ref' name="ReferenceA"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Mahdi</arg><arg name="first1">JG</arg><arg name="author2">Mahdi, AJ, Mahdi, AJ, Bowen, ID</arg><arg name="title">The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential</arg><arg name="journal">Cell proliferation</arg><arg name="date">April 2006</arg><arg name="volume">39</arg><arg name="issue">2</arg><arg name="pages">147–55</arg><arg name="pmid">16542349</arg><arg name="doi">10.1111/j.1365-2184.2006.00377.x</arg></template></extension><space/>The new drug, formally acetylsalicylic acid, was named Aspirin by Bayer AG after the original<space/><link><target>botany</target><part>botanical</part></link><space/>name for meadowsweet,<space/><italics>Spiraea ulmaria</italics>, derived from &quot;acetyl&quot; and<space/><italics>Spirsure</italics>, an old German name for salicylic acid derived from the Latin<space/><italics>Spiraea ulmaria</italics>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Singer<space/></arg><arg name="first">H.<space/></arg><arg name="title">Ueber Aspirin<space/></arg><arg name="journal">Pflügers Archiv: European Journal of Physiology<space/></arg><arg name="volume">84<space/></arg><arg name="issue">11–12<space/></arg><arg name="year">1901<space/></arg><arg name="pages">527–546<space/></arg><arg name="doi">10.1007/BF01769129</arg></template></extension><space/>By 1899, Bayer was selling it around the world.<extension extension_name='ref' name="Jeffreys_73"><template><target>Harvnb</target><arg>Jeffreys</arg><arg>2005</arg><arg name="pp">73</arg></template></extension><space/>The popularity of aspirin grew over the first half of the 20th century, spurred by its supposed effectiveness in the wake of the<space/><link><target>Spanish flu pandemic</target></link><space/>of 1918. However, recent research suggests that the high death toll of the<space/><link><target>1918 flu pandemic#Aspirin poisoning</target><part>1918 flu may have been partly due to aspirin</part></link>, though this is controversial and not universally accepted.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Starko</arg><arg name="first1">Karen M.</arg><arg name="title"><space/>Salicylates and Pandemic Influenza Mortality, 1918–1919 Pharmacology, Pathology, and Historic Evidence<space/></arg><arg name="journal">Clinical Infectious Diseases</arg><arg name="volume">49</arg><arg name="year">2009</arg><arg name="doi">10.1086/606060</arg><arg name="issue">9</arg><arg name="pmid">19788357</arg><arg name="pages">1405–1410</arg></template></extension><space/>This theory gained support when a recent repetition of the 1918 flu outbreak, with the same virus, had a low fatality rate.Aspirin's profitability led to fierce competition and the proliferation of aspirin brands and products, especially after the American patent held by Bayer expired in 1917.<extension extension_name='ref' name="Jeffreys_136"><template><target>Harvnb</target><arg>Jeffreys</arg><arg>2005</arg><arg name="pp">136–142, 151–152</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.history.com/this-day-in-history.do?action</arg><arg name="title">Bayer patents aspirin – This Day in History – 3/6/1899<space/></arg><arg name="publisher">History.com<space/></arg><arg name="accessdate">11 May 2011</arg></template></extension></paragraph><paragraph>The popularity of aspirin declined after the market releases of<space/><link><target>paracetamol</target></link><space/>(acetaminophen) in 1956 and<space/><link><target>ibuprofen</target></link><space/>in 1969.<extension extension_name='ref' name="Jeffreys_212"><template><target>Harvnb</target><arg>Jeffreys</arg><arg>2005</arg><arg name="pp">212–217</arg></template></extension><space/>In the 1960s and 1970s,<space/><link><target>John Robert Vane</target><part>John Vane</part></link><space/>and others discovered the basic mechanism of aspirin's effects, while clinical trials and other studies from the 1960s to the 1980s established aspirin's efficacy as an anticlotting agent that reduces the risk of clotting diseases.<extension extension_name='ref' name="Jeffreys_226"><template><target>Harvnb</target><arg>Jeffreys</arg><arg>2005</arg><arg name="pp">226–231</arg></template></extension><space/>Aspirin sales revived considerably in the last decades of the 20th century, and remain strong in the 21st century, because of its widespread use as a preventive treatment for heart attacks and strokes.<extension extension_name='ref' name="Jeffreys_267"><template><target>Harvnb</target><arg>Jeffreys</arg><arg>2005</arg><arg name="pp">267–269</arg></template></extension></paragraph><paragraph>The first studies of the effect of aspirin on cardiac function and stroke prevention was carried out by Professor<space/><link><target>Peter Sleight</target></link>,<extension extension_name='ref'>http://www.theheart.org/fr/documents/satellite_programs/prevention/791993/biography/sleight.html</extension><space/>Emeritus Professor of Cardiovascular Medicine at<space/><link><target>Oxford University</target></link>, in the early 1970s.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.prnewswire.com/news-releases/research-confirms-and-points-to-future-aspirin-uses-for-disease-prevention-75958547.html<space/></arg><arg name="title">Research Confirms and Points to Future Aspirin Uses For Disease Prevention – re><space/>BERLIN, Dec. 1 /PRNewswire/<space/></arg><arg name="publisher">Prnewswire.com<space/></arg><arg name="date"><space/></arg><arg name="accessdate">2014-05-05</arg></template></extension><space/>Sleight and his research team at Oxford led the way and formed the foundation for the research into the use of aspirin in the prevention of other medical conditions.</paragraph><heading level='3'>Trademark</heading><paragraph>Due to allowing the use of &quot;Aspirin&quot; for years by other manufacturing chemists, despite the patent-infringing nature of the use, and its own failure to use the name for its own product when it began selling direct, Bayer lost its trademark in 1918, affirmed by court appeal in 1921.<extension extension_name='ref'><template><target>cite court</target><arg name="litigants">Bayer Co. v. United Drug Co.<space/></arg><arg name="vol">272<space/></arg><arg name="reporter">F.<space/></arg><arg name="opinion">505<space/></arg><arg name="pinpoint">p.512<space/></arg><arg name="court">S.D.N.Y<space/></arg><arg name="date">1921<space/></arg><arg name="url">https://cyber.law.harvard.edu/metaschool/fisher/domain/tmcases/bayer.htm<space/></arg><arg name="accessdate">2015-09-01<space/></arg><arg name="quote">Disregarding this, however, it was too late in the autumn of 1915 to reclaim the word which had already passed into the public domain. If the consuming public had once learned to know 'Aspirin' as the accepted name for the drug, perhaps it is true that an extended course of education might have added to it some proprietary meaning, but it would be very difficult to prove that it had been done in 17 months, and in any case the plaintiff does not try to prove it. [...] Yet, had it not been indifferent to the results of selling to the consumer, it could have protected itself just as well at the time when consumers began to buy directly as in 1915. Nothing would have been easier than to insist that the tablet makers should market the drug in small tin boxes bearing the plaintiff's name, or to take over the sale just as it did later. Instead of this, they allowed the manufacturing chemists to build up this part of the demand without regard to the trade-mark. Having made that bed, they must be content to lie in it. Hence it appears to me that nothing happening between October, 1915, and March, 1917, will serve to turn the word into a trade-mark.</arg></template></extension><space/>Today, aspirin is a generic word in Australia, France, India, Ireland, New Zealand, Pakistan, Jamaica, Colombia, the Philippines, South Africa, the United Kingdom and the United States.<extension extension_name='ref'><template><target>Cite book</target><arg name="title"><space/>Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers</arg><arg name="author"><space/>CBE Style Manual Committee; Huth, Edward J.</arg><arg name="publisher"><space/>Cambridge University Press</arg><arg name="year"><space/>1994</arg><arg name="page"><space/>164</arg><arg name="url">https://books.google.com/books?id</arg><arg name="isbn"><space/>978-0-521-47154-1</arg></template></extension>Aspirin, with a capital &quot;A&quot;, remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 80 other countries, where the trademark is owned by Bayer, using acetylsalicylic acid in all markets, but using different packaging and physical aspects for each.<extension extension_name='ref'><template><target>Cite news</target><arg name="url">http://www.cbc.ca/health/story/2009/05/28/f-aspirin-studies.html
</arg><arg name="work">CBC News<space/></arg><arg name="title">Aspirin: the versatile drug<space/></arg><arg name="date">28 May 2009</arg></template></extension><extension extension_name='ref'><preblock><preline><template><target>Cite journal</target><arg name="last"><space/>Cheng<space/></arg><arg name="first"><space/>Tsung O.<space/></arg><arg name="title"><space/>The History of Aspirin<space/></arg><arg name="journal"><space/>Texas Heart Institute Journal<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>392–393<space/></arg><arg name="pmid"><space/>17948100<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmc"><space/>1995051<space/></arg></template></preline></preblock></extension></paragraph><paragraph>Aspirin is the<space/><link><target>British Approved Name</target><part>BAN</part></link><space/>and<space/><link><target>United States Adopted Name</target><part>USAN</part></link>.</paragraph><heading level='2'>Compendial status</heading><list type='bullet'><listitem><link><target>United States Pharmacopeia</target></link><extension extension_name='ref' name="asa"><template><target>cite web</target><arg name="last"><space/>[[Sigma Aldrich]]
<space/></arg><arg name="title"><space/>Aspirin
<space/></arg><arg name="url"><space/>http://www.sigmaaldrich.com/catalog/ProductDetail.do?lang</arg><arg name="accessdate">13 July 2009
</arg></template><space/><template><target>Dead link</target><arg name="date">April 2012</arg><arg name="bot">H3llBot</arg></template></extension></listitem><listitem><link><target>British Pharmacopoeia</target></link><extension extension_name='ref' name="ibp"><template><target>cite web</target><arg name="last"><space/>[[British Pharmacopoeia]]
<space/></arg><arg name="title"><space/>Index BP 2009
<space/></arg><arg name="url"><space/>http://www.pharmacopoeia.co.uk/pdf/2009_index.pdf
<space/></arg><arg name="accessdate">13 July 2009</arg></template></extension></listitem></list><heading level='2'>Veterinary use</heading><paragraph>Aspirin is sometimes used for pain relief or as an anticoagulant in veterinary medicine, primarily in dogs and sometimes horses, although newer medications with fewer side effects are generally used instead.</paragraph><paragraph>Both dogs and horses are susceptible to the gastrointestinal side effects associated with salicylates, but it is a convenient treatment for arthritis in older dogs, and has shown some promise in cases of<space/><link><target>laminitis</target></link><space/>in horses.<extension extension_name='ref'><template><target>cite web</target><arg name="last"><space/>Crosby</arg><arg name="first"><space/>Janet Tobiassen</arg><arg name="title"><space/>Veterinary Questions and Answers</arg><arg name="publisher"><space/>About.com</arg><arg name="year"><space/>2006</arg><arg name="url"><space/>http://vetmedicine.about.com/cs/altvetmedgeneral/a/dogcataspirin.htm</arg><arg name="accessdate">5 September 2007</arg><arg name="archiveurl"><space/>https://web.archive.org/web/20070908151020/http://vetmedicine.about.com/cs/altvetmedgeneral/a/dogcataspirin.htm</arg><arg name="archivedate"><space/>8 September 2007<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><extension extension_name='ref' name="CambridgeH"><template><target>Cite journal</target><arg name="author">Cambridge H, Lees P, Hooke RE, Russell CS</arg><arg name="title">Antithrombotic actions of aspirin in the horse<space/></arg><arg name="journal">Equine Vet J<space/></arg><arg name="volume">23<space/></arg><arg name="issue">2<space/></arg><arg name="pages">123–7<space/></arg><arg name="year">1991<space/></arg><arg name="pmid">1904347</arg><arg name="doi">10.1111/j.2042-3306.1991.tb02736.x</arg><arg name="last2">Lees<space/></arg><arg name="last3">Hooke<space/></arg><arg name="last4">Russell<space/></arg></template></extension><space/>It is no longer commonly used for cases of laminitis, as it could be counterproductive for treatment.Aspirin should be used in animals only under the direct supervision of a<space/><link><target>veterinarian</target></link>; in particular, cats lack the<space/><link><target>glucuronide</target></link><space/>conjugates that aid in the excretion of aspirin, making it potentially toxic.<extension extension_name='ref'><template><target>cite book</target><arg name="editor">Lappin, Michael R.</arg><arg name="title">Feline internal medicine secrets</arg><arg name="year">2001</arg><arg name="publisher">Hanley & Belfus</arg><arg name="location">Philadelphia</arg><arg name="isbn">1-56053-461-3</arg><arg name="page">160</arg></template></extension><space/>No clinical signs of toxicosis occurred when cats were given 25&amp;nbsp;mg/kg of aspirin every 48 hours for 4 weeks.<extension extension_name='ref'>http://www.merckmanuals.com/vet/toxicology/toxicities_from_human_drugs/analgesics_toxicity.html</extension>The dose recommended in cats for relief of pain and fever is 10&amp;nbsp;mg/kg every 48 hours.<extension extension_name='ref'>http://www.ansci.cornell.edu/plants/toxcat/toxcat.html</extension></paragraph><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>Further reading</heading><list type='bullet'><listitem><template><target>Cite book</target><arg name="last1">Jeffreys<space/></arg><arg name="first1">Diarmuid<space/></arg><arg name="title"><space/>Aspirin: The Remarkable Story of a Wonder Drug</arg><arg name="publisher"><space/>Bloomsbury USA</arg><arg name="date"><space/>11 August 2005</arg><arg name="isbn">1-58234-600-3</arg><arg name="ref">harv</arg></template></listitem></list><heading level='2'>External links</heading><paragraph><template><target>Commons</target><arg>Aspirin</arg></template></paragraph><list type='bullet'><listitem><link type='external' href='http://www.nextbio.com/b/home/home.nb?q=aspirin'>NextBio Aspirin Entry</link></listitem><listitem><link type='external' href='https://in.news.yahoo.com/scientific-review-finds-aspirin-significantly-cuts-cancer-rates-005137509--finance.html'>Aspirin Cuts Cancer Rates</link></listitem><listitem><link type='external' href='http://www.med.mcgill.ca/mjm/issues/v02n02/aspirin.html'>The History of Aspirin</link></listitem><listitem><link type='external' href='http://www.periodicvideos.com/videos/mv_aspirin.htm'>Aspirin</link><space/>at<space/><italics><link><target>The Periodic Table of Videos</target></link></italics><space/>(University of Nottingham)</listitem><listitem><link type='external' href='http://www.howstuffworks.com/aspirin'>How Aspirin works</link></listitem><listitem><link type='external' href='http://www.creatingtechnology.org/biomed/aspirin.htm'>The science behind aspirin</link></listitem><listitem><link type='external' href='http://pubs.acs.org/subscribe/journals/mdd/v03/i08/html/10health.html'>Take two: Aspirin</link>, New uses and new dangers are still being discovered as aspirin enters its 2nd century. Shauna Roberts, American Chemical Society</listitem><listitem><template><target>Cite encyclopedia</target><arg name="last"><space/>Ling</arg><arg name="first"><space/>Greg</arg><arg name="title"><space/>Aspirin</arg><arg name="encyclopedia"><space/>How Products are Made</arg><arg name="volume"><space/>1</arg><arg name="publisher"><space/>Thomson Gale</arg><arg name="year"><space/>2005</arg><arg name="url"><space/>http://www.madehow.com/Volume-1/Aspirin.html</arg></template></listitem><listitem><link type='external' href='http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Aspirin'>U.S. National Library of Medicine: Drug Information Portal Aspirin</link></listitem><listitem><link type='external' href='http://www.cdc.gov/niosh/npg/npgd0010.html'>CDC NIOSH Pocket Guide to Chemical Hazards Acetylsalicylic Acid</link></listitem></list><paragraph><template><target>Antithrombotics</target></template><template><target>Anti-inflammatory and antirheumatic products</target></template><template><target>Analgesics</target></template><template><target>Acne Agents</target></template><template><target>Salicylates</target></template><template><target>Prostanoidergics</target></template></paragraph><paragraph><template><target>Authority control</target></template></paragraph><paragraph><link><target>Category:Aspirin</target><part></part></link><link><target>Category:Non-steroidal anti-inflammatory drugs</target></link><link><target>Category:Antiplatelet drugs</target></link><link><target>Category:Equine medications</target></link><link><target>Category:Benzoic acids</target></link><link><target>Category:Salicylates</target></link><link><target>Category:World Health Organization essential medicines</target></link><link><target>Category:German inventions</target></link><link><target>Category:Acetate esters</target></link></paragraph></article>